<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Cytokine storm</title><meta name="description" content="A cytokine storm is a life-threatening systemic inflammatory syndrome characterized by the excessive release of pro-inflammatory cytokines from overactivated immune cells, resulting in widespread endothelial dysfunction, tissue damage, and potential multi-organ failure. This dysregulated response often features elevated circulating levels of interleukins (such as IL-6 and IL-1), tumor necrosis factor-alpha (TNF-α), interferons, and chemokines, which amplify immune cell recruitment and..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="cytokine release syndrome, CRS, hypercytokinemia"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Cytokine_storm"/><meta property="og:title" content="Cytokine storm"/><meta property="og:description" content="A cytokine storm is a life-threatening systemic inflammatory syndrome characterized by the excessive release of pro-inflammatory cytokines from overactivated immune cells, resulting in widespread endothelial dysfunction, tissue damage, and potential multi-organ failure. This dysregulated response often features elevated circulating levels of interleukins (such as IL-6 and IL-1), tumor necrosis factor-alpha (TNF-α), interferons, and chemokines, which amplify immune cell recruitment and..."/><meta property="og:url" content="https://grokipedia.com/page/Cytokine_storm"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Cytokine storm"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:45.531Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Cytokine storm"/><meta name="twitter:description" content="A cytokine storm is a life-threatening systemic inflammatory syndrome characterized by the excessive release of pro-inflammatory cytokines from overactivated immune cells, resulting in widespread endothelial dysfunction, tissue damage, and potential multi-organ failure. This dysregulated response often features elevated circulating levels of interleukins (such as IL-6 and IL-1), tumor necrosis factor-alpha (TNF-α), interferons, and chemokines, which amplify immune cell recruitment and..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="7c601fc441081a62db8331cdaa544861-d38791aca51da752-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=7c601fc441081a62db8331cdaa544861,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.8263220351047249,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>⌘</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>⌘</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#cytokine-storm" class="transition-opacity hover:opacity-100 opacity-50">Cytokine storm</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#definition-and-characteristics" class="transition-opacity hover:opacity-100 opacity-50">Definition and Characteristics</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#core-definition-and-pathological-features" class="transition-opacity hover:opacity-100 opacity-50">Core Definition and Pathological Features</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#distinction-from-cytokine-release-syndrome" class="transition-opacity hover:opacity-100 opacity-50">Distinction from Cytokine Release Syndrome</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pathophysiology" class="transition-opacity hover:opacity-100 opacity-50">Pathophysiology</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#mechanisms-of-immune-dysregulation" class="transition-opacity hover:opacity-100 opacity-50">Mechanisms of Immune Dysregulation</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#key-cytokines-and-feedback-loops" class="transition-opacity hover:opacity-100 opacity-50">Key Cytokines and Feedback Loops</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#etiology-and-triggers" class="transition-opacity hover:opacity-100 opacity-50">Etiology and Triggers</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#infectious-triggers" class="transition-opacity hover:opacity-100 opacity-50">Infectious Triggers</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#iatrogenic-and-non-infectious-triggers" class="transition-opacity hover:opacity-100 opacity-50">Iatrogenic and Non-Infectious Triggers</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#clinical-presentation" class="transition-opacity hover:opacity-100 opacity-50">Clinical Presentation</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#symptoms-and-progression" class="transition-opacity hover:opacity-100 opacity-50">Symptoms and Progression</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#associated-complications-and-organ-involvement" class="transition-opacity hover:opacity-100 opacity-50">Associated Complications and Organ Involvement</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#diagnosis-and-monitoring" class="transition-opacity hover:opacity-100 opacity-50">Diagnosis and Monitoring</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#laboratory-biomarkers" class="transition-opacity hover:opacity-100 opacity-50">Laboratory Biomarkers</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#diagnostic-challenges-and-differential-diagnosis" class="transition-opacity hover:opacity-100 opacity-50">Diagnostic Challenges and Differential Diagnosis</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#treatment-approaches" class="transition-opacity hover:opacity-100 opacity-50">Treatment Approaches</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#supportive-and-symptomatic-management" class="transition-opacity hover:opacity-100 opacity-50">Supportive and Symptomatic Management</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pharmacological-interventions" class="transition-opacity hover:opacity-100 opacity-50">Pharmacological Interventions</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#controversies-and-alternative-perspectives" class="transition-opacity hover:opacity-100 opacity-50">Controversies and Alternative Perspectives</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#role-in-major-diseases" class="transition-opacity hover:opacity-100 opacity-50">Role in Major Diseases</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#cytokine-storm-in-viral-infections-including-covid-19" class="transition-opacity hover:opacity-100 opacity-50">Cytokine Storm in Viral Infections Including COVID-19</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#cytokine-storm-in-immunotherapies-and-graft-versus-host-disease" class="transition-opacity hover:opacity-100 opacity-50">Cytokine Storm in Immunotherapies and Graft-Versus-Host Disease</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#cytokine-storm-in-autoimmune-and-other-conditions" class="transition-opacity hover:opacity-100 opacity-50">Cytokine Storm in Autoimmune and Other Conditions</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#historical-development" class="transition-opacity hover:opacity-100 opacity-50">Historical Development</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pre-1990s-observations" class="transition-opacity hover:opacity-100 opacity-50">Pre-1990s Observations</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#coining-of-the-term-and-early-research-1990s-2000s" class="transition-opacity hover:opacity-100 opacity-50">Coining of the Term and Early Research (1990s-2000s)</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#evolution-during-pandemics-and-recent-insights-2010s-2025" class="transition-opacity hover:opacity-100 opacity-50">Evolution During Pandemics and Recent Insights (2010s-2025)</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#ongoing-research-and-future-directions" class="transition-opacity hover:opacity-100 opacity-50">Ongoing Research and Future Directions</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#recent-discoveries-2023-2025" class="transition-opacity hover:opacity-100 opacity-50">Recent Discoveries (2023-2025)</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#emerging-therapies-and-prevention-strategies" class="transition-opacity hover:opacity-100 opacity-50">Emerging Therapies and Prevention Strategies</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="cytokine-storm" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Cytokine storm<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7"><br/>
A cytokine storm is a life-threatening systemic inflammatory syndrome characterized by the excessive release of pro-inflammatory cytokines from overactivated immune cells, resulting in widespread endothelial dysfunction, tissue damage, and potential multi-organ failure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_80qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> This dysregulated response often features elevated circulating levels of interleukins (such as IL-6 and IL-1), tumor necrosis factor-alpha (TNF-α), interferons, and chemokines, which amplify immune cell recruitment and perpetuate a vicious cycle of inflammation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> Empirically, cytokine storms have been documented in severe infections including bacterial sepsis, viral pneumonias like influenza and SARS-CoV-2, as well as non-infectious triggers such as chimeric antigen receptor T-cell (CAR-T) therapies and acute graft-versus-host disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_m0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> Key defining characteristics include rapid clinical deterioration with fever, hypotension, coagulopathy, and respiratory failure, where serum cytokine concentrations correlate strongly with disease severity and mortality risk, as evidenced by prospective studies measuring biomarkers like IL-6 and TNF-α in critically ill patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_s0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> While therapeutic interventions targeting specific cytokines (e.g., IL-6 inhibitors) have shown efficacy in modulating storms induced by immunotherapies, their application in infection-related cases remains contentious due to variable causal roles and risks of secondary infections from immunosuppression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_100qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_120qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<h2 id="definition-and-characteristics" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Definition and Characteristics<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="core-definition-and-pathological-features" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Core Definition and Pathological Features<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">A cytokine storm is defined as a life-threatening systemic inflammatory syndrome characterized by elevated circulating levels of cytokines, acute inflammatory symptoms, and secondary organ dysfunction that exceeds the typical response to an underlying trigger, such as infection, or cytokine-driven organ failure in the absence of a pathogen.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_42abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> This condition arises from dysregulated immune hyperactivation, where innate immune cells like macrophages and neutrophils, along with adaptive immune cells such as T cells, release excessive pro-inflammatory mediators in a self-perpetuating manner.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_82abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Pathologically, cytokine storms involve positive feedback loops amplifying inflammation through mechanisms like pyroptosis, apoptosis, and necroptosis, triggered by pathways such as the PANoptosome complex and inflammasome activation (e.g., NLRP3). Key cytokines implicated include interferon-gamma (IFN-γ), interleukin-1 (IL-1), IL-6, tumor necrosis factor (TNF), and IL-18, which synergistically drive endothelial damage, vascular permeability, and coagulopathy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_42qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> Empirical evidence from conditions like sepsis and hemophagocytic lymphohistiocytosis shows markedly elevated serum levels of these cytokines—e.g., IL-6 often exceeding 100 pg/mL and correlating with severity—alongside biomarkers such as C-reactive protein (CRP &gt;100 mg/L), ferritin (&gt;10,000 ng/mL), and D-dimer (&gt;1,000 ng/mL), reflecting widespread tissue injury and hemostatic imbalance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_82qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">These features culminate in capillary leak syndrome, acute respiratory distress syndrome (ARDS), and multiorgan failure affecting the lungs, kidneys, liver, and cardiovascular system, with mortality rates approaching 30-50% in severe cases depending on the trigger and host factors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> The pathology is distinguished by its failure to resolve inflammation, leading to collateral host damage rather than targeted pathogen clearance, as evidenced by histopathological findings of diffuse alveolar damage and microvascular thrombosis in affected tissues.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_83abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<h3 id="distinction-from-cytokine-release-syndrome" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Distinction from Cytokine Release Syndrome<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Although the terms &quot;cytokine storm&quot; and &quot;cytokine release syndrome&quot; (CRS) describe overlapping phenomena of excessive cytokine-mediated inflammation, they differ in historical origins, primary triggers, and clinical connotations. CRS was coined to characterize the acute, therapy-induced release of cytokines following infusion of muromonab-CD3 (OKT3), a monoclonal antibody used for immunosuppression, reflecting a targeted immune activation by exogenous agents.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_44abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Cytokine storm, by contrast, emerged as a descriptor for more diffuse, self-perpetuating hyperinflammatory states, initially in graft-versus-host disease and later in infectious contexts like sepsis, where endogenous immune dysregulation amplifies beyond initial triggers, leading to widespread tissue damage and organ failure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_84abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Key distinctions arise in etiology and pathophysiology. CRS predominantly occurs as an iatrogenic complication of adoptive cell therapies, such as CAR T-cell treatments for malignancies, or bispecific antibodies like blinatumomab, often presenting as a graded, reversible event responsive to interventions like interleukin-6 blockade (e.g., tocilizumab), with standardized severity scales from bodies like the American Society for Transplantation and Cellular Therapy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_44qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Cytokine storm, however, typically denotes infection-driven cascades—exemplified by elevated interleukin-1β in bacterial sepsis or interferon-γ patterns in viral cases like severe COVID-19—featuring sustained feedback loops, higher cytokine diversity, and variable treatment efficacy, as anti-cytokine therapies effective in CRS often underperform in pathogen-induced storms due to differing immunomodulatory imbalances.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_84qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Clinically, differentiation relies on context rather than symptoms alone, as both manifest with fever, capillary leak, and multi-organ involvement, complicating separation (e.g., CAR T-cell CRS versus sepsis-induced storm).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_45abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Cytokine storm implies a broader syndrome potentially encompassing hemophagocytic lymphohistiocytosis-like features or monogenic disorders, whereas CRS emphasizes quantifiable release amenable to prophylaxis in therapeutic settings, underscoring the importance of etiology-specific diagnostics like pathogen assays or therapy history to guide management.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_85abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup></span>
<h2 id="pathophysiology" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Pathophysiology<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="mechanisms-of-immune-dysregulation" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Mechanisms of Immune Dysregulation<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">A cytokine storm arises from dysregulated activation of the innate immune system, where pattern recognition receptors (PRRs) on macrophages, dendritic cells, and other sentinel cells detect pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs), initiating signaling through pathways such as NF-κB and IRF3/7. This leads to rapid transcription of pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, and IFN-α/β, which in controlled responses contain infection but escalate uncontrollably when regulatory mechanisms fail, such as insufficient negative feedback from IL-10 or SOCS proteins.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_46qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_66qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Dysregulation often stems from genetic defects in primary forms (e.g., mutations in PRR signaling or perforin/granzyme pathways in hemophagocytic lymphohistiocytosis) or overwhelming stimuli in secondary forms, amplifying cytokine output beyond physiological thresholds.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Amplification occurs via positive feedback loops where initial cytokines recruit and activate additional immune effectors; for instance, IL-1β and TNF-α induce endothelial expression of adhesion molecules (e.g., ICAM-1, VCAM-1), promoting leukocyte transmigration and further local inflammation that spills systemically.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_47abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> These cytokines also prime inflammasomes (e.g., NLRP3), triggering pyroptosis in infected or stressed cells, which releases additional DAMPs like HMGB1 and ATP, perpetuating PRR stimulation in a self-reinforcing cycle.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_87abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> In adaptive immunity, dysregulated antigen presentation by activated dendritic cells drives excessive T-cell proliferation, particularly Th1 and CD8+ subsets producing IFN-γ, which hyperstimulates macrophages to secrete more TNF-α and IL-6, while T-cell exhaustion (marked by PD-1 upregulation) impairs resolution, allowing innate overdrive to dominate.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Endothelial and coagulation dysregulation exacerbates the storm, as cytokines like IL-6 and TNF-α disrupt vascular integrity via downregulation of junctional proteins (e.g., VE-cadherin), causing leakage, edema, and microvascular thrombosis through platelet activation and tissue factor expression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_47qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> Complement system hyperactivation, often via alternative pathway dysregulation, deposits C3a/C5a anaphylatoxins that further amplify cytokine release from mast cells and neutrophils.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_87qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> In severe cases, such as sepsis or viral infections, failure of lymphocyte-mediated cytotoxicity (e.g., reduced NK and CD8+ T-cell function) prevents clearance of infected cells, sustaining antigen-driven loops and preventing transition to anti-inflammatory phases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> These mechanisms collectively override homeostatic checks, leading to multiorgan failure from diffuse inflammation rather than the primary trigger.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<h3 id="key-cytokines-and-feedback-loops" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Key Cytokines and Feedback Loops<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In cytokine storms, the primary pro-inflammatory cytokines driving pathology include interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interferon-gamma (IFN-γ), and interleukin-18 (IL-18), which are markedly elevated and coordinate systemic inflammation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_48qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_88qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> IL-6 serves as a central mediator, produced by macrophages and other immune cells, stimulating acute-phase protein synthesis in the liver while promoting T-cell differentiation and further cytokine release from endothelial cells and leukocytes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> TNF-α, secreted mainly by activated macrophages, induces endothelial activation, vascular permeability, and apoptosis in various cell types, exacerbating tissue damage and coagulopathy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup> IL-1β synergizes with TNF-α and IL-6 to amplify fever, hypotension, and lung injury by recruiting neutrophils and disrupting barrier functions in endothelium and epithelium.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_s8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_108qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">These cytokines establish self-reinforcing positive feedback loops that perpetuate hyperinflammation, often through reciprocal activation of immune cells and soluble mediators. For instance, initial pathogen recognition via Toll-like receptors triggers IL-1β and TNF-α release, which in turn upregulate IL-6 production and activate NF-κB pathways in macrophages, leading to exponential amplification without adequate negative regulation like IL-10 suppression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_49abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_89abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> IFN-γ and IL-18, derived from natural killer and T cells, enhance macrophage cytotoxicity and IFN-γ signaling, creating loops with TNF-α that promote cell death and release of damage-associated molecular patterns (DAMPs), further fueling cytokine secretion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> This interplay lacks sufficient counter-regulatory mechanisms, such as soluble cytokine receptors, resulting in unchecked escalation toward multi-organ failure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<h2 id="etiology-and-triggers" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Etiology and Triggers<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="infectious-triggers" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Infectious Triggers<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">
Infectious agents, particularly viruses and bacteria causing severe systemic infections, represent primary triggers of cytokine storm by inducing hyperactivation of innate immune responses, leading to uncontrolled release of pro-inflammatory cytokines such as IL-6, TNF-α, and IFN-γ.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Viral pathogens often provoke this through rapid replication in host tissues, activating pattern recognition receptors like TLRs and RIG-I, which amplify signaling cascades resulting in excessive cytokine production.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> Bacterial infections, especially those progressing to sepsis, similarly escalate via recognition of pathogen-associated molecular patterns, such as lipopolysaccharides in gram-negative bacteria or peptidoglycan in gram-positive ones, driving macrophage and neutrophil hypersecretion of cytokines.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_eaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Among viruses, coronaviruses including SARS-CoV-2, the etiological agent of COVID-19, frequently elicit cytokine storms in severe cases, with autopsy studies revealing lung tissue infiltration by hyperactivated T cells and monocytes alongside elevated plasma levels of IL-2, IL-7, IL-10, and MCP-1.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup> Influenza A subtypes, notably H5N1 and H1N1, trigger analogous responses, with H5N1 infections documented to cause mortality rates exceeding 50% in humans partly due to IFN-β, IL-6, and chemokine storms damaging pulmonary endothelium.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> Other viral culprits encompass hemorrhagic fever agents like Ebola virus and dengue virus, where endothelial disruption and immune cell lysis culminate in systemic inflammation, as observed in outbreaks with case fatality rates up to 90% for Ebola.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Herpesviruses such as Epstein-Barr virus, cytomegalovirus, and herpes simplex virus also precipitate storms in immunocompromised hosts, often via chronic antigenic stimulation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_obabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Bacterial triggers predominantly involve sepsis from pathogens like <em>Staphylococcus aureus</em>, <em>Streptococcus pyogenes</em> (group A streptococcus), and gram-negative enteric bacteria, where disseminated infection leads to endotoxin-mediated activation of Toll-like receptor 4, precipitating coagulopathies, fever, and multi-organ failure through TNF-α and IL-1 surges.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> In gram-positive sepsis, superantigens from <em>Streptococcus</em> or <em>Staphylococcus</em> species nonspecifically activate up to 20% of T cells, bypassing normal antigen presentation and yielding massive cytokine output, as evidenced in toxic shock syndrome cases with mortality rates around 30-70% without intervention.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_sbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> These infectious triggers underscore the causal role of pathogen burden and host immune priming in storm initiation, with outcomes influenced by viral load thresholds or bacterial dissemination speed.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<h3 id="iatrogenic-and-non-infectious-triggers" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Iatrogenic and Non-Infectious Triggers<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Iatrogenic triggers of cytokine storm often stem from therapeutic interventions that intentionally activate the immune system, leading to uncontrolled cytokine release. Chimeric antigen receptor (CAR) T-cell therapy, used in treating certain hematologic malignancies, exemplifies this, as infused engineered T cells rapidly expand and engage tumor antigens, prompting massive cytokine production including interleukin-6 (IL-6), interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> This results in cytokine release syndrome (CRS), a severe manifestation affecting 42–100% of patients, with grade 3 or higher severity in 0–46% depending on the CAR-T construct and patient factors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup> Similarly, bispecific T-cell engagers and superagonistic monoclonal antibodies, such as the anti-CD28 antibody TGN1412 tested in a 2006 clinical trial, have induced acute cytokine storms through polyclonal T-cell activation, causing multi-organ failure in healthy volunteers.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ccqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Anti-CD3 monoclonal antibodies like muromonab-CD3 (OKT3), historically used for acute rejection in organ transplantation, also provoke CRS via T-cell crosslinking and cytokine cascades.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Allogeneic hematopoietic stem cell transplantation (HSCT) represents another key iatrogenic pathway, particularly through acute graft-versus-host disease (GVHD), where donor T cells recognize host antigens as foreign, triggering a dysregulated inflammatory response.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> This &quot;cytokine storm&quot; in GVHD involves elevated levels of IL-1, TNF-α, and IL-6, amplifying tissue damage in skin, liver, and gastrointestinal tract, with incidence rates of acute GVHD reaching 30–50% in matched sibling donor transplants.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Reduced-intensity conditioning regimens in HSCT can alter cytokine profiles but do not eliminate this risk, as evidenced by persistent elevations in pro-inflammatory mediators post-transplant.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cdabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Non-infectious triggers independent of direct medical intervention include primary immunodeficiencies and autoinflammatory disorders. Hemophagocytic lymphohistiocytosis (HLH), particularly familial forms driven by genetic mutations in perforin or adaptor proteins like MUNC13-4, leads to unchecked macrophage and T-cell activation with hypercytokinemia, often without precipitating infection.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Secondary HLH associated with malignancies, such as lymphomas, or autoimmune conditions like macrophage activation syndrome (MAS) in systemic juvenile idiopathic arthritis, similarly manifests as cytokine storm through defective negative feedback in immune signaling pathways.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> Trauma and acute pancreatitis can provoke localized then systemic cytokine release via damage-associated molecular patterns (DAMPs), though these are less consistently classified as full cytokine storms compared to immunotherapeutic or GVHD contexts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cdqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> In all cases, these triggers highlight failures in immune homeostasis rather than external pathogens, underscoring the role of endogenous danger signals or genetic predispositions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gdqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<h2 id="clinical-presentation" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Clinical Presentation<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="symptoms-and-progression" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Symptoms and Progression<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">Cytokine storm manifests initially with systemic inflammatory symptoms such as persistent high fever, chills, severe fatigue, muscle and joint pain (myalgia and arthralgia), headache, and loss of appetite.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> These early signs arise from the massive release of pro-inflammatory cytokines like IL-6, TNF-α, and IFN-γ, which activate immune cells and endothelial cells, leading to widespread inflammation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_afqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Progression often escalates rapidly within hours to days, characterized by hemodynamic instability including hypotension and tachycardia, due to vascular leakage and increased vascular permeability induced by cytokines.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup> Respiratory symptoms intensify with hypoxia, cough, and shortness of breath, frequently culminating in acute respiratory distress syndrome (ARDS) from alveolar damage and pulmonary edema.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_agabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In advanced stages, cytokine storm leads to multi-organ dysfunction, encompassing acute kidney injury, hepatic failure, coagulopathy such as disseminated intravascular coagulation (DIC), cytopenias, and neurological alterations including confusion or encephalopathy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup> Cardiovascular complications like cardiomyopathy and shock may occur, driven by TNF-α and IL-1 effects on cardiac tissue and vasculature.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_agqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup> Without intervention, this cascade results in septic shock-like state and high mortality, with progression influenced by the inciting trigger&#x27;s severity and host factors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_egqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ggqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup></span>
<h3 id="associated-complications-and-organ-involvement" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Associated Complications and Organ Involvement<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">![Cytokine release following SARS-CoV-2 infection resulting in ARDS][float-right]
Cytokine storm induces systemic hyperinflammation that precipitates multi-organ dysfunction through mechanisms including endothelial damage, vascular leakage, and coagulopathy, often culminating in shock and failure of vital organs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Excessive cytokine levels, such as IL-6 and TNF-α, promote capillary permeability and microthrombosis, impairing tissue perfusion across multiple systems.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup> This process frequently results in acute respiratory distress syndrome (ARDS) in the lungs, characterized by diffuse alveolar damage and hypoxemic respiratory failure, with mortality rates exceeding 40% in severe cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_chqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Cardiovascular involvement manifests as myocardial depression, arrhythmias, and cardiogenic shock due to direct cytokine-mediated impairment of cardiac contractility and coronary microvasculature dysfunction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> Elevated levels of proinflammatory cytokines correlate with troponin release and left ventricular dysfunction, contributing to hemodynamic instability.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup> Renal complications include acute kidney injury (AKI), driven by hypoperfusion from shock, tubular necrosis, and inflammatory infiltration, with incidence rates up to 50% in critically ill patients experiencing cytokine release.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ciabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup> Hepatic dysfunction arises from ischemic hepatitis and cytokine-induced cholestasis, evidenced by marked elevations in transaminases and bilirubin.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_giabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Neurological sequelae encompass encephalopathy, seizures, and stroke risk from cerebral edema and thromboembolic events secondary to hypercoagulability.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup> Hematologic derangements, such as disseminated intravascular coagulation (DIC), exacerbate organ ischemia through widespread microvascular thrombosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> These complications underscore the need for early recognition, as unchecked progression leads to refractory multi-organ failure with mortality approaching 60-80% in fulminant cytokine storm syndromes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ciqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_eiqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<h2 id="diagnosis-and-monitoring" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Diagnosis and Monitoring<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="laboratory-biomarkers" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Laboratory Biomarkers<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Laboratory biomarkers for cytokine storm reflect systemic hyperinflammation, macrophage activation, and secondary organ dysfunction, though no single marker is diagnostic; instead, a constellation of elevations supports clinical suspicion and guides monitoring. Pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor (TNF), and interferon-γ (IFN-γ) are characteristically elevated in serum, with IL-6 levels often exceeding 80 pg/mL associated with severe outcomes in various triggers like infections and immunotherapies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> Soluble interleukin-2 receptor (sIL-2R or CD25) and interleukin-18 (IL-18) further indicate T-cell and macrophage hyperactivity, respectively, with sIL-2R &gt;3900 U/mL and high IL-18/free IL-18 ratios correlating with macrophage activation syndrome severity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ckabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gkabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Acute-phase reactants provide indirect but accessible evidence of inflammation. C-reactive protein (CRP) is universally elevated, often &gt;100 mg/L in severe cases, serving as a rapid prognostic indicator.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Hyperferritinemia, typically &gt;1000 ng/mL, signals iron dysregulation and macrophage involvement, strongly predicting poor prognosis in syndromes overlapping with cytokine storm such as hemophagocytic lymphohistiocytosis (HLH).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ckqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> Procalcitonin may rise in bacterial superinfections complicating the storm, aiding differentiation from pure cytokine-driven processes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gkqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Hematological and tissue damage markers highlight secondary effects. Lymphopenia (&lt;1.0 × 10^9/L lymphocytes) and thrombocytopenia reflect immune exhaustion and consumption, while elevated lactate dehydrogenase (LDH) indicates cellular injury.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Coagulation abnormalities, including D-dimer &gt;1 μg/mL, underscore endothelial damage and thrombotic risk, often preceding disseminated intravascular coagulation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> In immunotherapy-induced cytokine release syndrome (CRS), such as after CAR-T cells, ferritin, CRP, and LDH trends from baseline inform grading and tocilizumab eligibility per ASTCT consensus, though grading emphasizes clinical features over labs.31691-4/fulltext) <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_clabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Serial monitoring of these biomarkers tracks response to interventions like IL-6 blockade, with declining IL-6 and CRP levels correlating with de-escalation of organ support.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Elevated glycoprotein 130 (gp130) and interleukin-1 receptor antagonist (IL-1RA) may predict storm risk pre-emptively in high-risk therapies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Limitations include variability across triggers—e.g., higher cytokine peaks in CAR-T versus viral storms—and the need for context-specific interpretation to avoid over-reliance on isolated values.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_clqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<h3 id="diagnostic-challenges-and-differential-diagnosis" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Diagnostic Challenges and Differential Diagnosis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Diagnosis of cytokine storm is inherently challenging due to the absence of a pathognomonic test or universally accepted diagnostic criteria, relying instead on a constellation of clinical features—such as fever, hypotension, and multiorgan dysfunction—correlated with nonspecific laboratory evidence of hyperinflammation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> This syndrome manifests as excessive cytokine release exceeding the expected response to an underlying trigger, but quantifying &quot;excess&quot; remains subjective without standardized thresholds.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> Elevated biomarkers like ferritin (frequently &gt;10,000 ng/mL), C-reactive protein (CRP &gt;100 mg/L), D-dimer, lactate dehydrogenase (LDH), and cytokines such as interleukin-6 (IL-6 &gt;100 pg/mL) and interferon-gamma (IFN-γ) provide supportive evidence, yet these markers lack specificity and are routinely elevated in myriad critical illnesses, complicating attribution to cytokine storm.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cmqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> Practical barriers further impede diagnosis, including the infrequency of cytokine assays in clinical settings due to high costs, limited availability, and prolonged turnaround times, often delaying intervention until organ failure ensues.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gmqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Distinguishing cytokine storm from mimics requires contextual evaluation of the inciting event (e.g., infection versus immunotherapy) alongside targeted testing to exclude alternatives.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> <strong>Sepsis and septic shock</strong> present the most frequent overlap, sharing fever, endothelial leak, and cytokine elevation, but sepsis typically features microbial evidence (e.g., positive blood cultures) and higher procalcitonin or IL-1β levels, with early phases showing subdued T-cell activation compared to the pronounced CD8^+ T-cell proliferation (e.g., &gt;7% CD38^high/HLA-DR^+ CD8^+ T cells via flow cytometry) characteristic of cytokine storm in hemophagocytic contexts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cnabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup> This T-cell marker offers high diagnostic utility, with 100% sensitivity and 89% specificity for differentiating such storms from sepsis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gnabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Hemophagocytic lymphohistiocytosis (HLH)</strong> and <strong>macrophage activation syndrome (MAS)</strong>—a rheumatic variant of secondary HLH—closely resemble cytokine storm through shared hyperferritinemia, cytopenias, and coagulopathy, often fulfilling partial HLH-2004 criteria (e.g., splenomegaly, hypofibrinogenemia &lt;150 mg/dL, triglycerides &gt;265 mg/dL, or detectable hemophagocytosis in bone marrow).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_anqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> HLH diagnostic tools like the HScore (incorporating age, immunosuppression, and cytopenias) or HLH-2004 probability models (&gt;80% for scores ≥169) aid delineation, particularly when genetic defects (e.g., PRF1 mutations) or soluble IL-2 receptor (&gt;7,900 U/mL) are assessed, though these may not apply uniformly to non-HLH cytokine storms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_enqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> MAS, prevalent in systemic juvenile idiopathic arthritis, emphasizes ferritin:triglyceride ratios &gt;16 for early flagging amid disease flares.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_inqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup> Other differentials, such as acute respiratory distress syndrome (ARDS) or iatrogenic reactions in CAR-T therapy, necessitate exclusion via imaging, infection workup, and grading scales like ASTCT for cytokine release syndrome, underscoring the need for multidisciplinary integration to avoid misattribution.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mnqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></span>
<h2 id="treatment-approaches" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Treatment Approaches<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="supportive-and-symptomatic-management" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Supportive and Symptomatic Management<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Supportive management of cytokine storm prioritizes stabilization of vital functions and prevention of irreversible organ damage through intensive care measures, often in an ICU setting, while addressing symptoms such as fever and hypotension. This approach complements efforts to control the underlying trigger and applies across contexts like infections, immunotherapies, and sepsis, where hyperinflammation leads to capillary leak, vasodilation, and tissue hypoxia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">Hemodynamic support begins with intravenous fluid resuscitation to counter hypovolemia from capillary leak and third-spacing, typically using crystalloids, followed by vasopressors such as norepinephrine if hypotension persists despite adequate volume replacement; low-dose vasopressors suffice for grade 2 severity, while high-dose or multiple agents indicate grade 3 or higher.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> In severe cases involving cardiac compromise, such as fulminant myocarditis, mechanical circulatory support like intra-aortic balloon pump (IABP) can elevate systolic blood pressure by over 20 mmHg and reduce heart rate by 20-30 beats per minute, or extracorporeal membrane oxygenation (ECMO) for refractory shock.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aqabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Respiratory support escalates based on hypoxemia severity: low-flow oxygen (less than 40% FiO₂) for mild cases, non-invasive ventilation for moderate distress, and mechanical ventilation with lung-protective strategies for acute respiratory distress syndrome (ARDS), which frequently complicates cytokine storm due to alveolar damage and edema.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup> For renal involvement manifesting as acute kidney injury, continuous renal replacement therapy (CRRT) removes excess fluid and inflammatory mediators while supporting electrolyte balance and acid-base homeostasis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Symptomatic relief targets fever and discomfort with antipyretics like acetaminophen, avoiding non-steroidal anti-inflammatory drugs due to risks of worsening renal function or bleeding in thrombocytopenic patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup> Close monitoring of biomarkers, vital signs, and organ function guides escalation, with empiric infection screening to rule out concurrent sepsis, ensuring supportive measures do not delay targeted interventions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Outcomes improve when these strategies prevent progression to multi-organ failure, though mortality remains high in grades 3-4 without prompt application.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_crabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<h3 id="pharmacological-interventions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Pharmacological Interventions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Corticosteroids, particularly dexamethasone, represent a cornerstone of pharmacological management for cytokine storm, particularly in severe cases associated with viral infections like COVID-19. The RECOVERY trial, involving over 2,100 hospitalized patients receiving invasive mechanical ventilation or oxygen, demonstrated that dexamethasone at 6 mg daily for up to 10 days reduced 28-day mortality by 35% in ventilated patients (rate ratio 0.65; 95% CI 0.51-0.81) and by 20% in those on oxygen without ventilation (rate ratio 0.80; 95% CI 0.70-0.92), without increasing harm in milder cases. This effect is attributed to suppression of proinflammatory cytokine production and T-cell activation, though high doses risk immunosuppression and secondary infections. Guidelines from bodies like the WHO recommend corticosteroids for patients requiring supplemental oxygen, based on this level 1 evidence, while cautioning against routine use in non-hypoxic cases due to potential delays in viral clearance.00880-7/fulltext)</span>
<span class="mb-4 block break-words text-[1em] leading-7">Interleukin-6 receptor antagonists, such as tocilizumab, target a key mediator of cytokine storm by blocking IL-6 signaling, which drives fever, C-reactive protein elevation, and vascular permeability. In the RECOVERY trial&#x27;s tocilizumab arm (4,116 patients), a single 8 mg/kg intravenous dose reduced 28-day mortality by 4% absolute risk (31% vs. 35%; rate ratio 0.86; 95% CI 0.77-0.96) in hospitalized COVID-19 patients on oxygen or ventilation, with benefits most pronounced in those with high C-reactive protein (&gt;75 mg/L). Meta-analyses of randomized trials confirm reduced progression to mechanical ventilation (odds ratio 0.72; 95% CI 0.59-0.87) and ICU admission, though efficacy wanes in moderate disease without hypoxia. Similar results apply to CAR-T cell therapy-induced cytokine release syndrome, where tocilizumab is FDA-approved, shortening resolution time by 3-7 days in pivotal trials. Risks include bacterial infections and hepatotoxicity, necessitating monitoring.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4sqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Janus kinase (JAK) inhibitors like baricitinib interrupt downstream signaling of multiple cytokines (e.g., IL-6, IFN-γ) via JAK-STAT pathway blockade, mitigating amplification in cytokine storm. The ACTT-2 trial (1,039 hospitalized COVID-19 patients) showed baricitinib 4 mg daily for up to 14 days, added to remdesivir, accelerated recovery by 1 day (median 7 vs. 8 days; rate ratio 1.16; 95% CI 1.01-1.35) and trended toward lower mortality (5.1% vs. 7.8%), particularly in ventilated subgroups. Meta-analyses indicate probable mortality reduction (risk ratio 0.74; 95% CI 0.60-0.92) in oxygen-dependent patients, independent of viral variants due to host-targeted action. Evidence extends to graft-versus-host disease, where ruxolitinib (a JAK1/2 inhibitor) resolved steroid-refractory cases in 50-60% of patients per phase 3 trials. Adverse events include thrombosis and infections, with contraindications in active malignancy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Interleukin-1 blockers, such as anakinra, inhibit IL-1-driven inflammation implicated in macrophage activation syndrome-like storms. Observational studies and meta-analyses in severe COVID-19 report 20-30% absolute mortality reductions (e.g., 27% vs. 54% in hyperinflammatory subgroups), with improved PaO2/FiO2 ratios and reduced mechanical ventilation needs in patients with ferritin &gt;3,000 ng/mL or CRP &gt;100 mg/L. However, randomized trials like the SAVE-MORE study showed mixed results, with benefits confined to early hyperinflammation (e.g., 28-day mortality 11.9% vs. 20.6%; hazard ratio 0.55; 95% CI 0.39-0.78) but no overall efficacy in broader cohorts. In hemophagocytic lymphohistiocytosis, anakinra adjunctively lowered ferritin and cytokines in pediatric cases, though etoposide remains primary. Dosing (100 mg subcutaneous daily) requires renal adjustment, with risks of injection-site reactions and neutropenia. Evidence quality varies, with stronger support from real-world data than some underpowered RCTs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Emerging agents include anti-TNF therapies (e.g., infliximab) and broad immunosuppressants like cyclosporine, but randomized evidence is limited; for instance, infliximab reduced intubation in small COVID-19 trials (18% vs. 37%) yet failed larger validations. Combination regimens (e.g., tocilizumab plus corticosteroids) enhance outcomes in refractory cases, as per cohort studies showing synergistic cytokine suppression, but increase infection risks warranting vigilant monitoring. Selection depends on trigger-specific pathophysiology, biomarker levels (e.g., IL-6 &gt;100 pg/mL favoring anti-IL-6), and contraindications, with no universal first-line beyond supportive care. Ongoing trials explore next-generation inhibitors, emphasizing personalized dosing to balance efficacy against immunosuppression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<h3 id="controversies-and-alternative-perspectives" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Controversies and Alternative Perspectives<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The applicability of the &quot;cytokine storm&quot; framework to severe COVID-19 has faced scrutiny, with critics arguing that cytokine elevations in affected patients are modest compared to classical storms in conditions like CAR-T cell therapy or acute macrophage activation syndrome, and that persistent lymphopenia rather than hypercytokinemia better characterizes the immunopathology. <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4vabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup> This perspective posits that overemphasizing cytokine blockade may divert attention from underlying viral persistence or endothelial dysfunction as primary drivers of organ failure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8vabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Immunosuppressive treatments, such as corticosteroids, exhibit context-dependent efficacy tied to disease stage; the RECOVERY trial demonstrated a 30% mortality reduction with dexamethasone (6 mg daily for up to 10 days) in hospitalized patients requiring oxygen or ventilation as of June 2020, yet early administration in non-hypoxic or viraemic phases risks prolonging viral replication and delaying recovery by blunting adaptive immunity. <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4vqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup> Similarly, interleukin-6 inhibitors like tocilizumab yield mixed outcomes: observational data from July 2020 linked it to 45% lower mortality in ventilated COVID-19 patients, and the REMAP-CAP trial (published 2021) confirmed survival benefits in critically ill cases, but randomized trials such as COVACTA (2021) found no significant reduction in ventilator-free days, while subtype analyses indicate potential harm in macrophage activation-like presentations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8vqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup>  <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cvqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup> These discrepancies highlight risks of secondary bacterial infections and the absence of universal biomarkers to guide timing, with anticytokine approaches failing broadly in non-COVID sepsis trials due to heterogeneous inflammatory phenotypes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gvqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Alternative viewpoints emphasize prophylaxis over reactive suppression, advocating early antiviral agents (e.g., remdesivir or nirmatrelvir-ritonavir initiated within 5-7 days of symptoms) to curtail viral load and preempt escalation to hyperinflammation, as supported by in vitro and observational data showing reduced cytokine induction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_50abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup> Some researchers propose adjunctive non-pharmacological measures, such as mesenchymal stem cell infusions to modulate immunity without broad suppression, though randomized evidence remains limited to small trials demonstrating feasibility in refractory cases as of 2021.00068-6/fulltext) Critics of cytokine-centric paradigms further argue for causal dissection via single-cell transcriptomics to distinguish adaptive from maladaptive responses, cautioning against empirical blockade absent mechanistic validation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_90abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup></span>
<h2 id="role-in-major-diseases" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Role in Major Diseases<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="cytokine-storm-in-viral-infections-including-covid-19" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Cytokine Storm in Viral Infections Including COVID-19<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">Cytokine storm manifests in severe viral infections as an dysregulated immune response involving massive release of pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interferons, leading to systemic inflammation, endothelial damage, and multi-organ failure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_52abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> In highly pathogenic viruses like H5N1 avian influenza, autopsies and clinical data from 1997 outbreaks revealed markedly elevated cytokine levels, with TNF-α concentrations exceeding 500 pg/mL in fatal cases compared to under 10 pg/mL in healthy controls, correlating with diffuse alveolar damage and high lethality rates approaching 60%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_92abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup> Similarly, during the 2009 H1N1 pandemic, severe cases exhibited hypercytokinemia, though less intense than H5N1, contributing to acute respiratory distress syndrome (ARDS) in approximately 10-15% of hospitalized patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In hemorrhagic fever viruses such as Ebola, cytokine storms arise from viral glycoprotein-mediated activation of monocytes and dendritic cells, triggering cascades of IL-6, IL-8, and TNF-α that promote vascular leakage and coagulopathy, with plasma levels of IL-6 reaching over 100 pg/mL in non-survivors versus under 20 pg/mL in survivors during the 2014-2016 West Africa outbreak.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_52qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> SARS-CoV-1 infections during the 2003 epidemic also featured elevated chemokines and cytokines, including IP-10 and MCP-1, associated with lymphopenia and progression to ARDS in fatal cases, mirroring patterns in other coronaviruses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_92qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup> These responses often stem from impaired viral clearance, where pattern recognition receptors like Toll-like receptors overstimulate innate immunity, amplifying inflammation beyond antiviral needs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For SARS-CoV-2 causing COVID-19, early 2020 reports from Wuhan described hyperinflammation in intensive care unit (ICU) patients, with IL-6 levels averaging 60-100 pg/mL in severe cases versus 10-20 pg/mL in mild ones, alongside elevations in CRP and ferritin, linking to respiratory failure and mortality rates of 20-30% in ventilated cohorts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_53abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup> However, subsequent analyses questioned the &quot;cytokine storm&quot; label, noting that peak cytokine concentrations in COVID-19 (e.g., IL-6 rarely exceeding 200 pg/mL) were substantially lower than in canonical cytokine release syndromes from CAR-T therapy (often &gt;1,000 pg/mL) or bacterial sepsis, suggesting instead a sustained low-grade hyperinflammation driven by persistent antigen and T-cell exhaustion rather than acute explosive release.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_93abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Longitudinal studies from 2020-2021 confirmed associations between early IL-6 spikes and poor outcomes, but causality remains debated, as elevations may reflect tissue hypoxia and secondary damage more than primary immunopathology.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Empirical evidence from interventions underscores this nuance: the RECOVERY trial in 2020-2021 demonstrated that dexamethasone reduced 28-day mortality by 30% in oxygenated COVID-19 patients, implicating glucocorticoid-sensitive inflammation, while tocilizumab (anti-IL-6 receptor) lowered mortality in ventilated patients by 4-10% in subset analyses, yet failed to benefit non-severe cases, indicating cytokine dysregulation contributes selectively to progression rather than universally driving severity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_53qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Recent 2023-2025 cohort comparisons further reveal that COVID-19 cytokine profiles differ from hemophagocytic lymphohistiocytosis or immunotherapy storms, with lower interferon-gamma and higher IL-10, potentially reflecting viral evasion of type I interferon responses early in infection, allowing later compensatory overdrive.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_93qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[58]</sup> Overall, while cytokine storms exacerbate viral pathogenesis across these infections, their intensity and therapeutic targeting efficacy vary, emphasizing the need for biomarker-stratified approaches over blanket suppression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<h3 id="cytokine-storm-in-immunotherapies-and-graft-versus-host-disease" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Cytokine Storm in Immunotherapies and Graft-Versus-Host Disease<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Cytokine release syndrome (CRS), a form of cytokine storm, arises in immunotherapies due to rapid activation of immune effector cells, leading to excessive cytokine production such as IL-6, IFN-γ, and TNF-α. In chimeric antigen receptor (CAR) T-cell therapies targeting CD19 for B-cell malignancies, CRS incidence ranges from 42% to 100%, with severe cases (grade 3 or higher) occurring in 0% to 46% of patients, typically manifesting within 1-2 weeks post-infusion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_54qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_74qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup> Risk factors include high disease burden, elevated baseline inflammatory markers, and product-specific factors like CAR T-cell dose and persistence.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup> A landmark historical event was the 2006 phase 1 trial of TGN1412, an anti-CD28 monoclonal antibody, where all six healthy volunteers experienced life-threatening CRS characterized by multi-organ failure from massive cytokine release, highlighting risks of polyclonal T-cell activation without antigen specificity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[61]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">CRS also occurs with T-cell engaging bispecific antibodies (e.g., blinatumomab for acute lymphoblastic leukemia or teclistamab for multiple myeloma), though generally milder than in CAR T therapy, with incidence up to 70% but severe events less frequent due to controllable dosing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_55abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[62]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_75abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[63]</sup> Management of CRS in these contexts relies on grading via tools like the Lee or ASTCT criteria, with interventions including IL-6 blockade via tocilizumab (effective in 69-100% of severe cases) and corticosteroids for refractory symptoms, alongside supportive care for hypotension and hypoxia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[64]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[65]</sup> Prophylactic strategies, such as pre-infusion corticosteroids, reduce incidence in high-risk settings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation, cytokine storm contributes to acute GVHD pathophysiology through a two-phase process: initial host tissue damage from conditioning regimens (chemotherapy/radiation) releases damage-associated molecular patterns and cytokines (e.g., IL-1, TNF-α), promoting donor T-cell activation; subsequent lipopolysaccharide translocation from gut barrier disruption amplifies systemic inflammation via a &quot;cytokine storm&quot; involving IFN-γ and other effectors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_55qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_75qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[68]</sup> Acute GVHD incidence post-transplant is 30-50% in matched settings, rising with mismatches, with cytokine dysregulation driving skin, liver, and gastrointestinal involvement.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[69]</sup> Chronic GVHD, affecting 30-70% of long-term survivors, features persistent cytokine mediation (e.g., IL-21, BAFF), sustaining B-cell and fibrotic responses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[70]</sup> Treatment targets include corticosteroids as first-line (response rates 50-70%), JAK inhibitors like ruxolitinib for steroid-refractory cases (improving symptoms in 50-60%), and cytokine-specific agents, though prophylaxis with calcineurin inhibitors and methotrexate reduces overall GVHD risk by 20-40%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_j5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[71]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup> Overlap exists with immunotherapy CRS, as both involve T-cell hyperactivation, informing shared therapeutic approaches like IL-6 inhibition in severe GVHD.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup></span>
<h3 id="cytokine-storm-in-autoimmune-and-other-conditions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Cytokine Storm in Autoimmune and Other Conditions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Macrophage activation syndrome (MAS), a severe complication of autoimmune and autoinflammatory diseases such as systemic juvenile idiopathic arthritis (sJIA) and systemic lupus erythematosus (SLE), exemplifies cytokine storm through uncontrolled macrophage and T-cell activation, leading to hemophagocytosis and multi-organ failure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_56qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[73]</sup> This hyperinflammatory state features markedly elevated levels of pro-inflammatory cytokines, including interleukin-6 (IL-6), interleukin-18 (IL-18), tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ), which amplify immune dysregulation and tissue damage.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_96qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup> In sJIA-associated MAS, serum IL-18 concentrations often exceed 100,000 pg/mL, far surpassing levels in uncomplicated disease, correlating with disease severity and hemophagocytic activity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In SLE, MAS occurs in approximately 3-7% of cases, particularly in pediatric-onset disease, where it triggers a cytokine storm superimposed on baseline autoimmunity, with rapid progression to disseminated intravascular coagulation and hepatic dysfunction if untreated.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_57abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[74]</sup> Elevated cytokines such as IL-6 and IL-10 in SLE-MAS patients reflect a shift from adaptive to innate immune dominance, driven by impaired natural killer cell cytotoxicity and persistent antigenic stimulation from immune complexes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_97abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[75]</sup> Case reports document ferritin levels surpassing 10,000 ng/mL alongside cytokine surges, underscoring MAS as a diagnostic overlap between SLE flares and secondary hemophagocytic lymphohistiocytosis (HLH).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[76]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Secondary HLH in autoimmune contexts, including adult-onset Still&#x27;s disease and rheumatoid arthritis (RA), similarly involves cytokine storm as a core pathogenic feature, with IFN-γ overproduction from activated T cells and macrophages perpetuating a feedback loop of inflammation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_57qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[77]</sup> In RA, while chronic synovial cytokine elevation (e.g., TNF-α and IL-6) contributes to joint erosion, acute cytokine storms are rarer but can emerge in treatment-refractory cases or overlaps with MAS, marked by systemic symptoms and elevated soluble IL-2 receptor levels exceeding 10,000 U/mL.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_97qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[78]</sup> Diagnostic criteria for HLH-2004, adapted for autoimmune triggers, require at least five of eight features, including hyperferritinemia (&gt;500 ng/mL) and cytopenias, often validated by cytokine profiling in these settings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[79]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Beyond rheumatic diseases, cytokine storms arise in other autoimmune conditions like autoinflammatory syndromes, where genetic defects in cytokine regulation (e.g., IL-1 pathway dysregulation) provoke episodic hyperinflammation akin to familial HLH.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_58abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[80]</sup> These events differ from infectious triggers by lacking external pathogens, relying instead on intrinsic immune imbalances that sustain cytokine release without resolution, as evidenced by transcriptomic studies showing persistent macrophage polarization.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_98abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[81]</sup> Early recognition via biomarkers like soluble CD163 and neopterin aids differentiation from disease flares, emphasizing the need for targeted cytokine blockade to mitigate mortality rates, which approach 20-30% in severe autoimmune-associated cases.00180-6/fulltext)</span>
<h2 id="historical-development" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Historical Development<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="pre-1990s-observations" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Pre-1990s Observations<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The pathological consequences of dysregulated cytokine release were initially observed in the context of endotoxic shock during the 1970s and 1980s, predating the formal recognition of cytokine storms. In 1975, Carswell et al. identified a serum factor, later named tumor necrosis factor (TNF), in mice treated with bacterial endotoxin, which induced hemorrhagic necrosis in transplanted tumor cells and mimicked aspects of systemic toxicity from gram-negative infections.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_59qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[82]</sup> This factor was purified and cloned by 1984, revealing its potent proinflammatory properties, including induction of fever, endothelial activation, and organ dysfunction similar to clinical septic shock.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_99qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[83]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Further experiments in the mid-1980s established TNF as a central mediator of endotoxin-induced lethality. In 1985, TNF was shown to be identical to cachectin, a macrophage-derived protein causing cachexia and metabolic derangements in chronic inflammatory states, with elevated levels observed in models of bacterial sepsis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[84]</sup> By 1986, administration of recombinant TNF reproduced the hemodynamic collapse, hypotension, and multiorgan failure characteristic of endotoxemia in animal models.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[85]</sup> Neutralization studies provided causal evidence: in 1987, Tracey et al. demonstrated that anti-TNF monoclonal antibodies prevented death from septic shock in primates bacteremic with <em>Escherichia coli</em>, highlighting TNF&#x27;s role in amplifying vascular permeability and coagulopathy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_haabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[86]</sup> These findings underscored a feedback loop where initial endotoxin exposure triggered macrophage cytokine release, escalating to self-sustaining hyperinflammation.</span>
<span class="mb-4 block break-words text-[1em] leading-7">In graft-versus-host disease (GVHD), pre-1990s research documented analogous hyperinflammatory cascades following allogeneic bone marrow transplantation. As early as the 1960s, acute GVHD was clinically observed as donor T-cell mediated tissue destruction, but 1980s rodent models revealed cytokine-driven amplification, with TNF and interleukin-1 (IL-1) promoting endothelial damage and epithelial apoptosis in gut and skin.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[87]</sup> Studies in lethally irradiated mice showed that donor lymphocyte infusion led to rapid elevations in serum TNF, correlating with lethality from bowel inflammation and secondary bacterial translocation, independent of direct cytotoxicity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[88]</sup> This cytokine-mediated escalation was noted to exacerbate conditioning regimen toxicity, such as from total body irradiation, by sustaining proinflammatory signaling in target organs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_daqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[89]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Early observations in other contexts, such as viral hemorrhagic fevers and severe bacterial infections, similarly pointed to unchecked cytokine activity without invoking the later &quot;storm&quot; terminology. For instance, 1980s assays in dengue shock syndrome detected high circulating TNF levels preceding vascular leak and hypotension, suggesting a common mechanism of immune overactivation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[90]</sup> These pre-molecular insights, derived from bioassays and limited immunoassays, emphasized causal links between microbial triggers, macrophage activation, and fatal systemic inflammation, laying groundwork for understanding cytokine dysregulation as a driver of mortality in critical illnesses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[91]</sup></span>
<h3 id="coining-of-the-term-and-early-research-1990s-2000s" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Coining of the Term and Early Research (1990s-2000s)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The term &quot;cytokine storm&quot; was first coined in 1993 by James L. Ferrara and colleagues to characterize the explosive release of proinflammatory cytokines, with interleukin-1 (IL-1) playing a pivotal effector role, in acute graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[92]</sup> Ferrara et al. described this as a cascading amplification of cytokine production by donor T cells and host tissues, leading to widespread endothelial activation, tissue necrosis, and multiorgan failure, distinguishing it from mere immune activation by its self-sustaining, storm-like intensity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[92]</sup> This framing drew on emerging evidence of cytokine dysregulation, where GVHD manifestations such as skin rash, diarrhea, and liver dysfunction were attributed not primarily to direct T-cell cytotoxicity but to secondary inflammatory mediators like IL-1 and tumor necrosis factor-alpha (TNF-α).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dcabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[93]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Throughout the 1990s, research solidified the cytokine storm model in GVHD through clinical correlations and murine models, revealing peak elevations of TNF-α, IL-1, and interferon-gamma (IFN-γ) within days of transplantation onset, correlating with grade III-IV acute GVHD incidence rates exceeding 50% in mismatched donors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> Preclinical studies demonstrated that neutralizing IL-1 via receptor antagonists reduced lethality by 40-60% in lethally irradiated mice, while anti-TNF monoclonal antibodies ameliorated gut and liver pathology, underscoring cytokines&#x27; causal role over alloantigen mismatch alone.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[92]</sup> These findings prompted early clinical explorations, including pilot trials of soluble TNF receptors, which showed modest reductions in GVHD-related mortality but highlighted challenges in timing and specificity amid the storm&#x27;s rapidity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[93]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">By the early 2000s, the paradigm extended to infectious contexts, particularly severe viral pneumonias, where autopsy data from H5N1 avian influenza cases (1997-2004 outbreaks) documented hypercytokinemia with IL-6 levels up to 100-fold above norms, driving diffuse alveolar damage and ARDS mortality rates near 60%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> This application reframed cytokine storms as a maladaptive host response amplifying pathogen clearance into systemic collapse, influencing sepsis models where similar TNF-α/IL-1 surges predicted 30-day mortality odds ratios of 3-5 in Gram-negative infections.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Such insights spurred targeted cytokine blockade trials, though mixed outcomes revealed context-dependent drivers, with GVHD storms favoring T-cell origins versus infection-triggered innate responses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ddabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[94]</sup></span>
<h3 id="evolution-during-pandemics-and-recent-insights-2010s-2025" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Evolution During Pandemics and Recent Insights (2010s-2025)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">
During the 2009-2010 H1N1 influenza pandemic, research identified cytokine storms as a key factor in severe and fatal cases, particularly among young adults. Autopsy studies revealed that peak viral loads in lungs correlated with markedly elevated levels of proinflammatory cytokines such as IL-6 and TNF-α, contributing to diffuse alveolar damage and rapid deterioration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[95]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_beabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[96]</sup> Analysis of severe pneumonia cases showed hyperactivation of cytokines including IL-6, IL-8, and MCP-1, which correlated with clinical severity, prolonged viral shedding, and higher mortality, distinguishing them from milder infections.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_feabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[96]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_jeabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[97]</sup> These findings advanced understanding of cytokine dysregulation in viral pandemics, prompting early explorations of immunomodulatory therapies, though widespread application lagged until later outbreaks.</span>
<span class="mb-4 block break-words text-[1em] leading-7">The 2019-2020 COVID-19 pandemic markedly accelerated research on cytokine storms, establishing them as a central driver of acute respiratory distress syndrome (ARDS) and multi-organ failure in severe cases. Elevated circulating levels of IL-6, IL-1β, TNF, and IP-10 were consistently observed in critically ill patients, with cytokine profiles differing from those in pandemic influenza by including higher Th2-associated mediators like IL-4 and IL-17A.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[98]</sup> Comparisons with H1N1 revealed shared hyperinflammation but unique COVID-19 features, such as impaired type I interferon responses and neutrophil extracellular traps exacerbating lung injury.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_deqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[98]</sup> This led to rapid clinical trials demonstrating benefits from IL-6 inhibitors like tocilizumab and corticosteroids such as dexamethasone, reducing mortality in ventilated patients by modulating excessive immune activation without broadly suppressing antiviral responses.30628-0/fulltext) <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_heqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Post-2020 insights have refined mechanistic models, identifying overactivation of the JAK/STAT pathway and PANoptosis—a proinflammatory cell death program—as amplifiers of cytokine release in COVID-19 and related syndromes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> In December 2024, studies uncovered novel triggers, including SARS-CoV-2-induced mitochondrial dysfunction in immune cells, which propagates hyperinflammation via altered energy metabolism and cytokine signaling cascades.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[99]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[100]</sup> By 2025, bibliometric analyses highlighted a surge in research hotspots, emphasizing targeted interventions like JAK inhibitors and cytokine-neutralizing nanosponges for pandemic preparedness, while underscoring persistent challenges in early detection via biomarkers.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[101]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> These developments have shifted focus from blanket immunosuppression to precision modulation, informed by empirical outcomes from COVID-19&#x27;s scale.</span>
<h2 id="ongoing-research-and-future-directions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Ongoing Research and Future Directions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="recent-discoveries-2023-2025" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Recent Discoveries (2023-2025)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In 2024, researchers identified a vagal sensory neuron-to-caudal nucleus of the solitary tract (cNST) neural circuit that bidirectionally controls systemic inflammation, with activation of dopamine beta-hydroxylase (DBH)-expressing cNST neurons suppressing pro-inflammatory cytokines such as IL-1β by approximately 70% while elevating anti-inflammatory IL-10 up to tenfold in lipopolysaccharide-challenged mice.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[102]</sup> This circuit&#x27;s silencing exacerbated cytokine release, increasing IL-1β levels from 200 to 800 pg/ml and reducing IL-10 from 750 to 250 pg/ml, whereas chemogenetic stimulation protected against lethal endotoxemia (90% survival rate) and dextran sulfate sodium-induced colitis by modulating vagal TRPA1 neurons for anti-inflammatory effects.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[102]</sup> Single-cell RNA sequencing and calcium imaging confirmed cytokine-responsive vagal afferents projecting to cNST, highlighting a brain-body axis for potential neuromodulatory interventions in sepsis and autoimmune cytokine storms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dgqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[102]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Computational protein design yielded de novo miniproteins in 2024 that antagonize key cytokine storm inducers IL-6 and IL-1β by binding their receptors with high affinity, such as IL-6Rmb10 (KD 300 pM) shifting IL-6 EC50 by 74.7-fold and IL-1Rmb81 (IC50 2.8 nM) reducing IL-1β-induced damage in human cardiac organoids.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[103]</sup> Developed via Rosetta docking of scaffolds to receptor interfaces, followed by yeast display screening and X-ray validation showing atomic-level fit, these ≤65-residue binders blocked signaling in bone marrow-derived cells and preserved organoid function against SARS-CoV-2-mimicking inflammation without off-target effects on related pathways.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[103]</sup> Their short half-life and thermostability position them as tunable alternatives to monoclonal antibodies for acute cytokine storms in infections or immunotherapies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dhabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[103]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A short-acting anti-IL-6 receptor monoclonal antibody, reported in early 2024, transiently blocks IL-6 signaling to inhibit hypoxia-inducible factor-1α (HIF1α) activation, thereby stabilizing vascular endothelium and curbing leakage in sepsis and burn models without the sustained immunosuppression of long-acting inhibitors. Preclinical data showed reduced tissue inflammation and improved survival in cytokine release syndrome akin to COVID-19 or acute respiratory distress, emphasizing targeted, time-limited intervention to preserve immune competence. Concurrently, a multi-institutional analysis pinpointed overactivation of immune response genes alongside renin-angiotensin-aldosterone system (RAAS) dysregulation as the precipitating trigger for COVID-19 cytokine storms, correlating this dual pathway with organ failure and elevated mortality in severe cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[104]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In 2025, macrophage studies demonstrated that elevating eukaryotic initiation factor 2 alpha (eIF2α) phosphorylation disrupts transcription-translation coupling, selectively inhibiting cytokine hyperproduction during inflammatory challenges and averting storm-like responses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[105]</sup> This mechanism, validated in vitro, underscores integrated stress response pathways as novel checkpoints for therapeutic modulation in sepsis and viral pathologies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[105]</sup></span>
<h3 id="emerging-therapies-and-prevention-strategies" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Emerging Therapies and Prevention Strategies<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Monoclonal antibodies targeting novel inflammatory mediators represent a key emerging therapy for mitigating cytokine storms. In preclinical murine models of sepsis induced by <em>Pseudomonas aeruginosa</em> or lipopolysaccharide, a humanized antibody against citrullinated histone H3 (hCitH3-mAb), administered at 20 mg/kg, disrupted a TLR2-calcium-PAD2 feedback loop that drives neutrophil extracellular trap (NET) formation and pyroptosis, resulting in significantly reduced levels of pro-inflammatory cytokines IL-6 and IL-1β, lower bacterial loads in lungs, spleen, and liver, and enhanced survival rates.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[106]</sup> Elevated serum CitH3 levels in human septic patients correlate with disease severity, supporting its role as a therapeutic target.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_djabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[106]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A separate humanized monoclonal antibody, developed to address sepsis-induced immune dysregulation, blocks excessive cytokine release while restoring macrophage function and preventing organ damage, such as lung injury, in mouse models without broadly suppressing adaptive immunity; as of August 2025, it has advanced to funded clinical trials at U.S. institutions, with preclinical data confirming safety and efficacy in halting storm progression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[107]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Small-molecule inhibitors of the JAK-STAT pathway, including ruxolitinib (a JAK1/2 inhibitor), have gained traction for cytokine release syndrome (CRS) in CAR-T cell therapies and hemophagocytic lymphohistiocytosis (HLH), where they attenuate signaling from multiple cytokines like IL-6, IFN-γ, and TNF-α; recent refinements emphasize selective inhibition to balance efficacy against infection risks, with phase 2/3 trials demonstrating reduced refractory cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> Anakinra, an IL-1 receptor antagonist, serves as an adjunct for steroid-resistant CRS, controlling inflammation and neurotoxicity in clinical settings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Novel delivery systems, such as cytokine nanosponges—nanoparticles coated with macrophage membranes—have shown preclinical promise in neutralizing excess cytokines in HLH mouse models, alleviating symptoms without systemic immunosuppression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> Mesenchymal stem cells (MSCs) exert immunomodulatory effects by polarizing macrophages toward an anti-inflammatory M2 phenotype and suppressing T-cell proliferation, with over 1,000 registered trials exploring their use in graft-versus-host disease and viral ARDS as of 2025, though outcomes vary due to cell sourcing heterogeneity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Prevention strategies prioritize biomarker-driven risk stratification, using metrics like the EASIX score, serum IL-6, ferritin, and CD8+ T-cell counts to identify at-risk patients early in conditions such as sepsis or immunotherapy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> In CAR-T protocols, prophylactic tocilizumab (IL-6 blockade, 8 mg/kg IV up to 4 doses) or anakinra reduces CRS incidence and severity, particularly in high-tumor-burden cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> For viral infections, rapid pathogen detection and initiation of antivirals within 1 hour, combined with cytokine monitoring, prevents escalation to storm; blood purification techniques, like β2-microglobulin adsorption columns, offer adjunctive support by depleting circulating IL-6 and TNF in septic patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dlabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> These approaches underscore the need for personalized timing, as indiscriminate early immunosuppression can exacerbate infections.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hlabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="https://www.nejm.org/doi/full/10.1056/NEJMra2026131" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMra2026131" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMra2026131</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9570384/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9570384/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9570384/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9310545/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9310545/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9310545/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7727315/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7727315/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7727315/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7079934/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7079934/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7079934/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3592351/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3592351/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3592351/</a></span></div></li><li id="https://www.nature.com/articles/s41591-020-1051-9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41591-020-1051-9" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41591-020-1051-9</a></span></div></li><li id="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2767939" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2767939" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2767939</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12000524/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12000524/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12000524/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7791954/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7791954/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7791954/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S1074761320302727" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S1074761320302727" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S1074761320302727</a></span></div></li><li id="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.589095/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.589095/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.589095/full</a></span></div></li><li id="https://www.nature.com/articles/s41392-025-02178-y" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41392-025-02178-y" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41392-025-02178-y</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7118634/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7118634/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7118634/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7799025/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7799025/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7799025/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7431332/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7431332/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7431332/</a></span></div></li><li id="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/cytokine-storm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/cytokine-storm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/cytokine-storm</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10289607/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10289607/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10289607/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11547016/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11547016/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11547016/</a></span></div></li><li id="https://jpmsonline.com/article/the-impact-of-cytokine-storms-on-severe-infectious-diseases-progression-a-narrative-review-720/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jpmsonline.com/article/the-impact-of-cytokine-storms-on-severe-infectious-diseases-progression-a-narrative-review-720/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jpmsonline.com/article/the-impact-of-cytokine-storms-on-severe-infectious-diseases-progression-a-narrative-review-720/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8165266/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8165266/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8165266/</a></span></div></li><li id="https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2021.827151/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2021.827151/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2021.827151/full</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/30586620/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/30586620/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/30586620/</a></span></div></li><li id="https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02148-6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02148-6" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02148-6</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S2405844024058006" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S2405844024058006" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S2405844024058006</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/8240742/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/8240742/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/8240742/</a></span></div></li><li id="https://www.astctjournal.org/article/S1083-8791%2805%2900846-3/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.astctjournal.org/article/S1083-8791%2805%2900846-3/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.astctjournal.org/article/S1083-8791%2805%2900846-3/fulltext</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7321048/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7321048/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7321048/</a></span></div></li><li id="https://virologyj.biomedcentral.com/articles/10.1186/s12985-020-01415-w" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://virologyj.biomedcentral.com/articles/10.1186/s12985-020-01415-w" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://virologyj.biomedcentral.com/articles/10.1186/s12985-020-01415-w</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8115911/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8115911/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8115911/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9007670/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9007670/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9007670/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8074652/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8074652/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8074652/</a></span></div></li><li id="https://virologyj.biomedcentral.com/articles/10.1186/s12985-022-01814-1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://virologyj.biomedcentral.com/articles/10.1186/s12985-022-01814-1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://virologyj.biomedcentral.com/articles/10.1186/s12985-022-01814-1</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8426723/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8426723/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8426723/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8241122/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8241122/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8241122/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8242812/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8242812/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8242812/</a></span></div></li><li id="https://ashpublications.org/blood/article/137/17/2337/474597/T-cell-activation-profiles-distinguish" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ashpublications.org/blood/article/137/17/2337/474597/T-cell-activation-profiles-distinguish" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ashpublications.org/blood/article/137/17/2337/474597/T-cell-activation-profiles-distinguish</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4074772/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4074772/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4074772/</a></span></div></li><li id="https://ashpublications.org/blood/article/124/2/188/32896/Current-concepts-in-the-diagnosis-and-management" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ashpublications.org/blood/article/124/2/188/32896/Current-concepts-in-the-diagnosis-and-management" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ashpublications.org/blood/article/124/2/188/32896/Current-concepts-in-the-diagnosis-and-management</a></span></div></li><li id="https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15124" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15124" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15124</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8828941/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8828941/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8828941/</a></span></div></li><li id="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2803480" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2803480" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2803480</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0953620521000169" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0953620521000169" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0953620521000169</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7681075/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7681075/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7681075/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8373392/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8373392/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8373392/</a></span></div></li><li id="https://journals.lww.com/10.1097/BOR.0000000000000822" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/10.1097/BOR.0000000000000822" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/10.1097/BOR.0000000000000822</a></span></div></li><li id="https://casereports.bmj.com/content/14/2/e241105" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://casereports.bmj.com/content/14/2/e241105" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://casereports.bmj.com/content/14/2/e241105</a></span></div></li><li id="https://www.michiganmedicine.org/health-lab/drug-calms-cytokine-storm-associated-45-lower-risk-dying-among-covid-19-patients" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.michiganmedicine.org/health-lab/drug-calms-cytokine-storm-associated-45-lower-risk-dying-among-covid-19-patients" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.michiganmedicine.org/health-lab/drug-calms-cytokine-storm-associated-45-lower-risk-dying-among-covid-19-patients</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8229480/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8229480/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8229480/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7994048/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7994048/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7994048/</a></span></div></li><li id="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.572635/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.572635/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.572635/full</a></span></div></li><li id="https://www.nature.com/articles/s41598-021-99291-z" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41598-021-99291-z" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41598-021-99291-z</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4711683/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4711683/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4711683/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7832378/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7832378/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7832378/</a></span></div></li><li id="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.659419/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.659419/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.659419/full</a></span></div></li><li id="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.01708/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.01708/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.01708/full</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7361342/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7361342/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7361342/</a></span></div></li><li id="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2832234" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2832234" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2832234</a></span></div></li><li id="https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.950923/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.950923/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.950923/full</a></span></div></li><li id="https://jitc.bmj.com/content/6/1/56" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jitc.bmj.com/content/6/1/56" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jitc.bmj.com/content/6/1/56</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa063842" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa063842" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa063842</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11739781/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11739781/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11739781/</a></span></div></li><li id="https://ashpublications.org/blood/article/143/16/1565/514709/Consensus-recommendations-on-the-management-of" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ashpublications.org/blood/article/143/16/1565/514709/Consensus-recommendations-on-the-management-of" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ashpublications.org/blood/article/143/16/1565/514709/Consensus-recommendations-on-the-management-of</a></span></div></li><li id="https://link.springer.com/article/10.1007/s44272-025-00044-0" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://link.springer.com/article/10.1007/s44272-025-00044-0" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://link.springer.com/article/10.1007/s44272-025-00044-0</a></span></div></li><li id="https://ashpublications.org/blood/article/130/21/2295/36661/Kinetics-and-biomarkers-of-severe-cytokine-release" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ashpublications.org/blood/article/130/21/2295/36661/Kinetics-and-biomarkers-of-severe-cytokine-release" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ashpublications.org/blood/article/130/21/2295/36661/Kinetics-and-biomarkers-of-severe-cytokine-release</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S1083879118315799" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S1083879118315799" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S1083879118315799</a></span></div></li><li id="https://ashpublications.org/blood/article/95/9/2754/125533/The-primacy-of-the-gastrointestinal-tract-as-a" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ashpublications.org/blood/article/95/9/2754/125533/The-primacy-of-the-gastrointestinal-tract-as-a" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ashpublications.org/blood/article/95/9/2754/125533/The-primacy-of-the-gastrointestinal-tract-as-a</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK538235/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK538235/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK538235/</a></span></div></li><li id="https://emedicine.medscape.com/article/429037-overview" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://emedicine.medscape.com/article/429037-overview" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://emedicine.medscape.com/article/429037-overview</a></span></div></li><li id="https://www.jci.org/articles/view/90593" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.jci.org/articles/view/90593" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.jci.org/articles/view/90593</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8417310/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8417310/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8417310/</a></span></div></li><li id="https://www.clinmedres.org/content/2/4/243" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.clinmedres.org/content/2/4/243" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.clinmedres.org/content/2/4/243</a></span></div></li><li id="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.00119/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.00119/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.00119/full</a></span></div></li><li id="https://link.springer.com/chapter/10.1007/978-3-031-59815-9_24" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://link.springer.com/chapter/10.1007/978-3-031-59815-9_24" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://link.springer.com/chapter/10.1007/978-3-031-59815-9_24</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/39117826/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/39117826/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/39117826/</a></span></div></li><li id="https://www.cureus.com/articles/258388-unleashing-the-cytokine-storm-a-case-of-macrophage-activation-syndrome-in-systemic-lupus-erythematosus" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cureus.com/articles/258388-unleashing-the-cytokine-storm-a-case-of-macrophage-activation-syndrome-in-systemic-lupus-erythematosus" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cureus.com/articles/258388-unleashing-the-cytokine-storm-a-case-of-macrophage-activation-syndrome-in-systemic-lupus-erythematosus</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/35819695/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/35819695/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/35819695/</a></span></div></li><li id="https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.40071" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.40071" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.40071</a></span></div></li><li id="https://jhoonline.biomedcentral.com/articles/10.1186/s13045-024-01621-x" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jhoonline.biomedcentral.com/articles/10.1186/s13045-024-01621-x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jhoonline.biomedcentral.com/articles/10.1186/s13045-024-01621-x</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/34681901/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/34681901/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/34681901/</a></span></div></li><li id="https://www.nature.com/articles/s41584-020-00571-1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41584-020-00571-1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41584-020-00571-1</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3380349/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3380349/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3380349/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5021902/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5021902/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5021902/</a></span></div></li><li id="https://centennial.rucares.org/index.php?page=Tumor_Necrosis_Factor" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://centennial.rucares.org/index.php?page=Tumor_Necrosis_Factor" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://centennial.rucares.org/index.php?page=Tumor_Necrosis_Factor</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11373197/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11373197/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11373197/</a></span></div></li><li id="https://www.nature.com/articles/330662a0" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/330662a0" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/330662a0</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4102708/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4102708/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4102708/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0006497120640897" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0006497120640897" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0006497120640897</a></span></div></li><li id="https://www.astctjournal.org/article/S1083-8791%2899%2970011-X/pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.astctjournal.org/article/S1083-8791%2899%2970011-X/pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.astctjournal.org/article/S1083-8791%2899%2970011-X/pdf</a></span></div></li><li id="https://link.springer.com/article/10.1007/s00281-017-0640-2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://link.springer.com/article/10.1007/s00281-017-0640-2" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://link.springer.com/article/10.1007/s00281-017-0640-2</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11847631/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11847631/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11847631/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/8442093/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/8442093/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/8442093/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/095279159390139J" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/095279159390139J" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/095279159390139J</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3294426/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3294426/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3294426/</a></span></div></li><li id="https://www.cidrap.umn.edu/h1n1-2009-pandemic-influenza/study-shows-cytokine-storm-fatal-2009-h1n1-cases" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cidrap.umn.edu/h1n1-2009-pandemic-influenza/study-shows-cytokine-storm-fatal-2009-h1n1-cases" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cidrap.umn.edu/h1n1-2009-pandemic-influenza/study-shows-cytokine-storm-fatal-2009-h1n1-cases</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3192778/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3192778/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3192778/</a></span></div></li><li id="https://academic.oup.com/cid/article/50/6/850/418325" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/cid/article/50/6/850/418325" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/cid/article/50/6/850/418325</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9422807/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9422807/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9422807/</a></span></div></li><li id="https://www.hopkinsmedicine.org/news/newsroom/news-releases/2024/12/a-cause-of-hyperinflammatory-response-in-lethal-covid19-identified" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.hopkinsmedicine.org/news/newsroom/news-releases/2024/12/a-cause-of-hyperinflammatory-response-in-lethal-covid19-identified" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.hopkinsmedicine.org/news/newsroom/news-releases/2024/12/a-cause-of-hyperinflammatory-response-in-lethal-covid19-identified</a></span></div></li><li id="https://news.weill.cornell.edu/news/2024/12/study-details-surprising-biological-mechanisms-underlying-severe-covid-19" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://news.weill.cornell.edu/news/2024/12/study-details-surprising-biological-mechanisms-underlying-severe-covid-19" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://news.weill.cornell.edu/news/2024/12/study-details-surprising-biological-mechanisms-underlying-severe-covid-19</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S240584402406986X" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S240584402406986X" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S240584402406986X</a></span></div></li><li id="https://www.nature.com/articles/s41586-024-07469-y" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41586-024-07469-y" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41586-024-07469-y</a></span></div></li><li id="https://www.nature.com/articles/s41467-024-50919-4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41467-024-50919-4" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41467-024-50919-4</a></span></div></li><li id="https://scitechdaily.com/johns-hopkins-scientists-uncover-hidden-trigger-behind-covid-19s-deadly-cytokine-storm/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://scitechdaily.com/johns-hopkins-scientists-uncover-hidden-trigger-behind-covid-19s-deadly-cytokine-storm/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://scitechdaily.com/johns-hopkins-scientists-uncover-hidden-trigger-behind-covid-19s-deadly-cytokine-storm/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S1567576924024871" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S1567576924024871" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S1567576924024871</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12343807/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12343807/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12343807/</a></span></div></li><li id="https://doi.org/10.1038/s41467-025-62788-6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1038/s41467-025-62788-6" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1038/s41467-025-62788-6</a></span></div></li></ol></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0" id="_R_" async=""></script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0\"}]\n"])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Cytokine_storm\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Cytokine_storm\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Cytokine_storm\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T12972,"])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,"# Cytokine storm\n\n![Cytokine release following SARS-CoV-2 infection resulting in ARDS related to COVID-19](./_assets_/Cytokine_release_following_SARS-Cov-2_infection_resulting_in_ARDS_related_to_COVID-19.png)  \nA cytokine storm is a life-threatening systemic inflammatory syndrome characterized by the excessive release of pro-inflammatory cytokines from overactivated immune cells, resulting in widespread endothelial dysfunction, tissue damage, and potential multi-organ failure.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9570384/) This dysregulated response often features elevated circulating levels of interleukins (such as IL-6 and IL-1), tumor necrosis factor-alpha (TNF-α), interferons, and chemokines, which amplify immune cell recruitment and perpetuate a vicious cycle of inflammation.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9310545/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7727315/) Empirically, cytokine storms have been documented in severe infections including bacterial sepsis, viral pneumonias like influenza and SARS-CoV-2, as well as non-infectious triggers such as chimeric antigen receptor T-cell (CAR-T) therapies and acute graft-versus-host disease.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7079934/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3592351/) Key defining characteristics include rapid clinical deterioration with fever, hypotension, coagulopathy, and respiratory failure, where serum cytokine concentrations correlate strongly with disease severity and mortality risk, as evidenced by prospective studies measuring biomarkers like IL-6 and TNF-α in critically ill patients.[](https://www.nature.com/articles/s41591-020-1051-9)[](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2767939) While therapeutic interventions targeting specific cytokines (e.g., IL-6 inhibitors) have shown efficacy in modulating storms induced by immunotherapies, their application in infection-related cases remains contentious due to variable causal roles and risks of secondary infections from immunosuppression.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12000524/)\n\n## Definition and Characteristics\n\n### Core Definition and Pathological Features\n\nA cytokine storm is defined as a life-threatening systemic inflammatory syndrome characterized by elevated circulating levels of cytokines, acute inflammatory symptoms, and secondary organ dysfunction that exceeds the typical response to an underlying trigger, such as infection, or cytokine-driven organ failure in the absence of a pathogen.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) This condition arises from dysregulated immune hyperactivation, where innate immune cells like macrophages and neutrophils, along with adaptive immune cells such as T cells, release excessive pro-inflammatory mediators in a self-perpetuating manner.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC9310545/)\n\nPathologically, cytokine storms involve positive feedback loops amplifying inflammation through mechanisms like pyroptosis, apoptosis, and necroptosis, triggered by pathways such as the PANoptosome complex and inflammasome activation (e.g., NLRP3). Key cytokines implicated include interferon-gamma (IFN-γ), interleukin-1 (IL-1), IL-6, tumor necrosis factor (TNF), and IL-18, which synergistically drive endothelial damage, vascular permeability, and coagulopathy.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9310545/) Empirical evidence from conditions like sepsis and hemophagocytic lymphohistiocytosis shows markedly elevated serum levels of these cytokines—e.g., IL-6 often exceeding 100 pg/mL and correlating with severity—alongside biomarkers such as C-reactive protein (CRP \u003e100 mg/L), ferritin (\u003e10,000 ng/mL), and D-dimer (\u003e1,000 ng/mL), reflecting widespread tissue injury and hemostatic imbalance.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC9570384/)\n\nThese features culminate in capillary leak syndrome, acute respiratory distress syndrome (ARDS), and multiorgan failure affecting the lungs, kidneys, liver, and cardiovascular system, with mortality rates approaching 30-50% in severe cases depending on the trigger and host factors.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9570384/) The pathology is distinguished by its failure to resolve inflammation, leading to collateral host damage rather than targeted pathogen clearance, as evidenced by histopathological findings of diffuse alveolar damage and microvascular thrombosis in affected tissues.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC9310545/)\n\n### Distinction from Cytokine Release Syndrome\n\nAlthough the terms \"cytokine storm\" and \"cytokine release syndrome\" (CRS) describe overlapping phenomena of excessive cytokine-mediated inflammation, they differ in historical origins, primary triggers, and clinical connotations. CRS was coined to characterize the acute, therapy-induced release of cytokines following infusion of muromonab-CD3 (OKT3), a monoclonal antibody used for immunosuppression, reflecting a targeted immune activation by exogenous agents.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) Cytokine storm, by contrast, emerged as a descriptor for more diffuse, self-perpetuating hyperinflammatory states, initially in graft-versus-host disease and later in infectious contexts like sepsis, where endogenous immune dysregulation amplifies beyond initial triggers, leading to widespread tissue damage and organ failure.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131)\n\nKey distinctions arise in etiology and pathophysiology. CRS predominantly occurs as an iatrogenic complication of adoptive cell therapies, such as CAR T-cell treatments for malignancies, or bispecific antibodies like blinatumomab, often presenting as a graded, reversible event responsive to interventions like interleukin-6 blockade (e.g., tocilizumab), with standardized severity scales from bodies like the American Society for Transplantation and Cellular Therapy.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) Cytokine storm, however, typically denotes infection-driven cascades—exemplified by elevated interleukin-1β in bacterial sepsis or interferon-γ patterns in viral cases like severe COVID-19—featuring sustained feedback loops, higher cytokine diversity, and variable treatment efficacy, as anti-cytokine therapies effective in CRS often underperform in pathogen-induced storms due to differing immunomodulatory imbalances.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC7791954/)\n\nClinically, differentiation relies on context rather than symptoms alone, as both manifest with fever, capillary leak, and multi-organ involvement, complicating separation (e.g., CAR T-cell CRS versus sepsis-induced storm).[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) Cytokine storm implies a broader syndrome potentially encompassing hemophagocytic lymphohistiocytosis-like features or monogenic disorders, whereas CRS emphasizes quantifiable release amenable to prophylaxis in therapeutic settings, underscoring the importance of etiology-specific diagnostics like pathogen assays or therapy history to guide management.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC7791954/)\n\n## Pathophysiology\n\n### Mechanisms of Immune Dysregulation\n\nA cytokine storm arises from dysregulated activation of the innate immune system, where pattern recognition receptors (PRRs) on macrophages, dendritic cells, and other sentinel cells detect pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs), initiating signaling through pathways such as NF-κB and IRF3/7. This leads to rapid transcription of pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, and IFN-α/β, which in controlled responses contain infection but escalate uncontrollably when regulatory mechanisms fail, such as insufficient negative feedback from IL-10 or SOCS proteins.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9310545/)[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) Dysregulation often stems from genetic defects in primary forms (e.g., mutations in PRR signaling or perforin/granzyme pathways in hemophagocytic lymphohistiocytosis) or overwhelming stimuli in secondary forms, amplifying cytokine output beyond physiological thresholds.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9310545/)\n\nAmplification occurs via positive feedback loops where initial cytokines recruit and activate additional immune effectors; for instance, IL-1β and TNF-α induce endothelial expression of adhesion molecules (e.g., ICAM-1, VCAM-1), promoting leukocyte transmigration and further local inflammation that spills systemically.[](https://www.sciencedirect.com/science/article/pii/S1074761320302727) These cytokines also prime inflammasomes (e.g., NLRP3), triggering pyroptosis in infected or stressed cells, which releases additional DAMPs like HMGB1 and ATP, perpetuating PRR stimulation in a self-reinforcing cycle.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9310545/) In adaptive immunity, dysregulated antigen presentation by activated dendritic cells drives excessive T-cell proliferation, particularly Th1 and CD8+ subsets producing IFN-γ, which hyperstimulates macrophages to secrete more TNF-α and IL-6, while T-cell exhaustion (marked by PD-1 upregulation) impairs resolution, allowing innate overdrive to dominate.[](https://www.sciencedirect.com/science/article/pii/S1074761320302727)[](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.589095/full)\n\nEndothelial and coagulation dysregulation exacerbates the storm, as cytokines like IL-6 and TNF-α disrupt vascular integrity via downregulation of junctional proteins (e.g., VE-cadherin), causing leakage, edema, and microvascular thrombosis through platelet activation and tissue factor expression.[](https://www.sciencedirect.com/science/article/pii/S1074761320302727) Complement system hyperactivation, often via alternative pathway dysregulation, deposits C3a/C5a anaphylatoxins that further amplify cytokine release from mast cells and neutrophils.[](https://www.nature.com/articles/s41392-025-02178-y) In severe cases, such as sepsis or viral infections, failure of lymphocyte-mediated cytotoxicity (e.g., reduced NK and CD8+ T-cell function) prevents clearance of infected cells, sustaining antigen-driven loops and preventing transition to anti-inflammatory phases.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9310545/) These mechanisms collectively override homeostatic checks, leading to multiorgan failure from diffuse inflammation rather than the primary trigger.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131)\n\n### Key Cytokines and Feedback Loops\n\nIn cytokine storms, the primary pro-inflammatory cytokines driving pathology include interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interferon-gamma (IFN-γ), and interleukin-18 (IL-18), which are markedly elevated and coordinate systemic inflammation.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) [](https://www.nature.com/articles/s41392-025-02178-y) IL-6 serves as a central mediator, produced by macrophages and other immune cells, stimulating acute-phase protein synthesis in the liver while promoting T-cell differentiation and further cytokine release from endothelial cells and leukocytes.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7118634/) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC7799025/) TNF-α, secreted mainly by activated macrophages, induces endothelial activation, vascular permeability, and apoptosis in various cell types, exacerbating tissue damage and coagulopathy.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7431332/) [](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/cytokine-storm) IL-1β synergizes with TNF-α and IL-6 to amplify fever, hypotension, and lung injury by recruiting neutrophils and disrupting barrier functions in endothelium and epithelium.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10289607/) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC11547016/)\n\nThese cytokines establish self-reinforcing positive feedback loops that perpetuate hyperinflammation, often through reciprocal activation of immune cells and soluble mediators. For instance, initial pathogen recognition via Toll-like receptors triggers IL-1β and TNF-α release, which in turn upregulate IL-6 production and activate NF-κB pathways in macrophages, leading to exponential amplification without adequate negative regulation like IL-10 suppression.[](https://www.nature.com/articles/s41392-025-02178-y) [](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.589095/full) IFN-γ and IL-18, derived from natural killer and T cells, enhance macrophage cytotoxicity and IFN-γ signaling, creating loops with TNF-α that promote cell death and release of damage-associated molecular patterns (DAMPs), further fueling cytokine secretion.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC9310545/) This interplay lacks sufficient counter-regulatory mechanisms, such as soluble cytokine receptors, resulting in unchecked escalation toward multi-organ failure.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9570384/)\n\n## Etiology and Triggers\n\n### Infectious Triggers\n\n![Cytokine release following SARS-CoV-2 infection](._assets_/Cytokine_release_following_SARS-Cov-2_infection_resulting_in_ARDS_related_to_COVID-19.png)\nInfectious agents, particularly viruses and bacteria causing severe systemic infections, represent primary triggers of cytokine storm by inducing hyperactivation of innate immune responses, leading to uncontrolled release of pro-inflammatory cytokines such as IL-6, TNF-α, and IFN-γ.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) Viral pathogens often provoke this through rapid replication in host tissues, activating pattern recognition receptors like TLRs and RIG-I, which amplify signaling cascades resulting in excessive cytokine production.[](https://www.nature.com/articles/s41392-025-02178-y) Bacterial infections, especially those progressing to sepsis, similarly escalate via recognition of pathogen-associated molecular patterns, such as lipopolysaccharides in gram-negative bacteria or peptidoglycan in gram-positive ones, driving macrophage and neutrophil hypersecretion of cytokines.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7079934/)\n\nAmong viruses, coronaviruses including SARS-CoV-2, the etiological agent of COVID-19, frequently elicit cytokine storms in severe cases, with autopsy studies revealing lung tissue infiltration by hyperactivated T cells and monocytes alongside elevated plasma levels of IL-2, IL-7, IL-10, and MCP-1.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) [](https://jpmsonline.com/article/the-impact-of-cytokine-storms-on-severe-infectious-diseases-progression-a-narrative-review-720/) Influenza A subtypes, notably H5N1 and H1N1, trigger analogous responses, with H5N1 infections documented to cause mortality rates exceeding 50% in humans partly due to IFN-β, IL-6, and chemokine storms damaging pulmonary endothelium.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8165266/) Other viral culprits encompass hemorrhagic fever agents like Ebola virus and dengue virus, where endothelial disruption and immune cell lysis culminate in systemic inflammation, as observed in outbreaks with case fatality rates up to 90% for Ebola.[](https://jpmsonline.com/article/the-impact-of-cytokine-storms-on-severe-infectious-diseases-progression-a-narrative-review-720/) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC9570384/) Herpesviruses such as Epstein-Barr virus, cytomegalovirus, and herpes simplex virus also precipitate storms in immunocompromised hosts, often via chronic antigenic stimulation.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131)\n\nBacterial triggers predominantly involve sepsis from pathogens like *Staphylococcus aureus*, *Streptococcus pyogenes* (group A streptococcus), and gram-negative enteric bacteria, where disseminated infection leads to endotoxin-mediated activation of Toll-like receptor 4, precipitating coagulopathies, fever, and multi-organ failure through TNF-α and IL-1 surges.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC7079934/) In gram-positive sepsis, superantigens from *Streptococcus* or *Staphylococcus* species nonspecifically activate up to 20% of T cells, bypassing normal antigen presentation and yielding massive cytokine output, as evidenced in toxic shock syndrome cases with mortality rates around 30-70% without intervention.[](https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2021.827151/full) These infectious triggers underscore the causal role of pathogen burden and host immune priming in storm initiation, with outcomes influenced by viral load thresholds or bacterial dissemination speed.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9310545/)\n\n### Iatrogenic and Non-Infectious Triggers\n\nIatrogenic triggers of cytokine storm often stem from therapeutic interventions that intentionally activate the immune system, leading to uncontrolled cytokine release. Chimeric antigen receptor (CAR) T-cell therapy, used in treating certain hematologic malignancies, exemplifies this, as infused engineered T cells rapidly expand and engage tumor antigens, prompting massive cytokine production including interleukin-6 (IL-6), interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α).[](https://pubmed.ncbi.nlm.nih.gov/30586620/) This results in cytokine release syndrome (CRS), a severe manifestation affecting 42–100% of patients, with grade 3 or higher severity in 0–46% depending on the CAR-T construct and patient factors.[](https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02148-6) Similarly, bispecific T-cell engagers and superagonistic monoclonal antibodies, such as the anti-CD28 antibody TGN1412 tested in a 2006 clinical trial, have induced acute cytokine storms through polyclonal T-cell activation, causing multi-organ failure in healthy volunteers.[](https://www.sciencedirect.com/science/article/pii/S2405844024058006) Anti-CD3 monoclonal antibodies like muromonab-CD3 (OKT3), historically used for acute rejection in organ transplantation, also provoke CRS via T-cell crosslinking and cytokine cascades.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9570384/)\n\nAllogeneic hematopoietic stem cell transplantation (HSCT) represents another key iatrogenic pathway, particularly through acute graft-versus-host disease (GVHD), where donor T cells recognize host antigens as foreign, triggering a dysregulated inflammatory response.[](https://pubmed.ncbi.nlm.nih.gov/8240742/) This \"cytokine storm\" in GVHD involves elevated levels of IL-1, TNF-α, and IL-6, amplifying tissue damage in skin, liver, and gastrointestinal tract, with incidence rates of acute GVHD reaching 30–50% in matched sibling donor transplants.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) Reduced-intensity conditioning regimens in HSCT can alter cytokine profiles but do not eliminate this risk, as evidenced by persistent elevations in pro-inflammatory mediators post-transplant.[](https://www.astctjournal.org/article/S1083-8791%2805%2900846-3/fulltext)\n\nNon-infectious triggers independent of direct medical intervention include primary immunodeficiencies and autoinflammatory disorders. Hemophagocytic lymphohistiocytosis (HLH), particularly familial forms driven by genetic mutations in perforin or adaptor proteins like MUNC13-4, leads to unchecked macrophage and T-cell activation with hypercytokinemia, often without precipitating infection.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9570384/) Secondary HLH associated with malignancies, such as lymphomas, or autoimmune conditions like macrophage activation syndrome (MAS) in systemic juvenile idiopathic arthritis, similarly manifests as cytokine storm through defective negative feedback in immune signaling pathways.[](https://www.nature.com/articles/s41392-025-02178-y) Trauma and acute pancreatitis can provoke localized then systemic cytokine release via damage-associated molecular patterns (DAMPs), though these are less consistently classified as full cytokine storms compared to immunotherapeutic or GVHD contexts.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9310545/) In all cases, these triggers highlight failures in immune homeostasis rather than external pathogens, underscoring the role of endogenous danger signals or genetic predispositions.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131)\n\n## Clinical Presentation\n\n### Symptoms and Progression\n\n![Cytokine release following SARS-CoV-2 infection resulting in ARDS](./_assets_/Cytokine_release_following_SARS-Cov-2_infection_resulting_in_ARDS_related_to_COVID-19.png)\n\nCytokine storm manifests initially with systemic inflammatory symptoms such as persistent high fever, chills, severe fatigue, muscle and joint pain (myalgia and arthralgia), headache, and loss of appetite.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7321048/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9570384/) These early signs arise from the massive release of pro-inflammatory cytokines like IL-6, TNF-α, and IFN-γ, which activate immune cells and endothelial cells, leading to widespread inflammation.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9310545/)\n\nProgression often escalates rapidly within hours to days, characterized by hemodynamic instability including hypotension and tachycardia, due to vascular leakage and increased vascular permeability induced by cytokines.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9570384/)[](https://virologyj.biomedcentral.com/articles/10.1186/s12985-020-01415-w) Respiratory symptoms intensify with hypoxia, cough, and shortness of breath, frequently culminating in acute respiratory distress syndrome (ARDS) from alveolar damage and pulmonary edema.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8115911/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9007670/)\n\nIn advanced stages, cytokine storm leads to multi-organ dysfunction, encompassing acute kidney injury, hepatic failure, coagulopathy such as disseminated intravascular coagulation (DIC), cytopenias, and neurological alterations including confusion or encephalopathy.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9310545/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8115911/) Cardiovascular complications like cardiomyopathy and shock may occur, driven by TNF-α and IL-1 effects on cardiac tissue and vasculature.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8074652/) Without intervention, this cascade results in septic shock-like state and high mortality, with progression influenced by the inciting trigger's severity and host factors.[](https://www.nature.com/articles/s41392-025-02178-y)[](https://jpmsonline.com/article/the-impact-of-cytokine-storms-on-severe-infectious-diseases-progression-a-narrative-review-720/)\n\n### Associated Complications and Organ Involvement\n\n![Cytokine release following SARS-CoV-2 infection resulting in ARDS][float-right]\nCytokine storm induces systemic hyperinflammation that precipitates multi-organ dysfunction through mechanisms including endothelial damage, vascular leakage, and coagulopathy, often culminating in shock and failure of vital organs.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) Excessive cytokine levels, such as IL-6 and TNF-α, promote capillary permeability and microthrombosis, impairing tissue perfusion across multiple systems.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9007670/) This process frequently results in acute respiratory distress syndrome (ARDS) in the lungs, characterized by diffuse alveolar damage and hypoxemic respiratory failure, with mortality rates exceeding 40% in severe cases.[](https://virologyj.biomedcentral.com/articles/10.1186/s12985-022-01814-1)\n\nCardiovascular involvement manifests as myocardial depression, arrhythmias, and cardiogenic shock due to direct cytokine-mediated impairment of cardiac contractility and coronary microvasculature dysfunction.[](https://www.nature.com/articles/s41392-025-02178-y) Elevated levels of proinflammatory cytokines correlate with troponin release and left ventricular dysfunction, contributing to hemodynamic instability.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8115911/) Renal complications include acute kidney injury (AKI), driven by hypoperfusion from shock, tubular necrosis, and inflammatory infiltration, with incidence rates up to 50% in critically ill patients experiencing cytokine release.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8426723/) Hepatic dysfunction arises from ischemic hepatitis and cytokine-induced cholestasis, evidenced by marked elevations in transaminases and bilirubin.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9007670/)\n\nNeurological sequelae encompass encephalopathy, seizures, and stroke risk from cerebral edema and thromboembolic events secondary to hypercoagulability.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9007670/) Hematologic derangements, such as disseminated intravascular coagulation (DIC), exacerbate organ ischemia through widespread microvascular thrombosis.[](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.589095/full) These complications underscore the need for early recognition, as unchecked progression leads to refractory multi-organ failure with mortality approaching 60-80% in fulminant cytokine storm syndromes.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9310545/)\n\n## Diagnosis and Monitoring\n\n### Laboratory Biomarkers\n\nLaboratory biomarkers for cytokine storm reflect systemic hyperinflammation, macrophage activation, and secondary organ dysfunction, though no single marker is diagnostic; instead, a constellation of elevations supports clinical suspicion and guides monitoring. Pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor (TNF), and interferon-γ (IFN-γ) are characteristically elevated in serum, with IL-6 levels often exceeding 80 pg/mL associated with severe outcomes in various triggers like infections and immunotherapies.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) [](https://www.nature.com/articles/s41392-025-02178-y) Soluble interleukin-2 receptor (sIL-2R or CD25) and interleukin-18 (IL-18) further indicate T-cell and macrophage hyperactivity, respectively, with sIL-2R \u003e3900 U/mL and high IL-18/free IL-18 ratios correlating with macrophage activation syndrome severity.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) [](https://www.nature.com/articles/s41392-025-02178-y)\n\nAcute-phase reactants provide indirect but accessible evidence of inflammation. C-reactive protein (CRP) is universally elevated, often \u003e100 mg/L in severe cases, serving as a rapid prognostic indicator.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) Hyperferritinemia, typically \u003e1000 ng/mL, signals iron dysregulation and macrophage involvement, strongly predicting poor prognosis in syndromes overlapping with cytokine storm such as hemophagocytic lymphohistiocytosis (HLH).[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) [](https://www.nature.com/articles/s41392-025-02178-y) Procalcitonin may rise in bacterial superinfections complicating the storm, aiding differentiation from pure cytokine-driven processes.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8241122/)\n\nHematological and tissue damage markers highlight secondary effects. Lymphopenia (\u003c1.0 × 10^9/L lymphocytes) and thrombocytopenia reflect immune exhaustion and consumption, while elevated lactate dehydrogenase (LDH) indicates cellular injury.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) Coagulation abnormalities, including D-dimer \u003e1 μg/mL, underscore endothelial damage and thrombotic risk, often preceding disseminated intravascular coagulation.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) In immunotherapy-induced cytokine release syndrome (CRS), such as after CAR-T cells, ferritin, CRP, and LDH trends from baseline inform grading and tocilizumab eligibility per ASTCT consensus, though grading emphasizes clinical features over labs.31691-4/fulltext) [](https://www.nejm.org/doi/full/10.1056/NEJMra2026131)\n\nSerial monitoring of these biomarkers tracks response to interventions like IL-6 blockade, with declining IL-6 and CRP levels correlating with de-escalation of organ support.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) Elevated glycoprotein 130 (gp130) and interleukin-1 receptor antagonist (IL-1RA) may predict storm risk pre-emptively in high-risk therapies.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) Limitations include variability across triggers—e.g., higher cytokine peaks in CAR-T versus viral storms—and the need for context-specific interpretation to avoid over-reliance on isolated values.[](https://www.nature.com/articles/s41392-025-02178-y)\n\n### Diagnostic Challenges and Differential Diagnosis\n\nDiagnosis of cytokine storm is inherently challenging due to the absence of a pathognomonic test or universally accepted diagnostic criteria, relying instead on a constellation of clinical features—such as fever, hypotension, and multiorgan dysfunction—correlated with nonspecific laboratory evidence of hyperinflammation.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7727315/) This syndrome manifests as excessive cytokine release exceeding the expected response to an underlying trigger, but quantifying \"excess\" remains subjective without standardized thresholds.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7727315/) Elevated biomarkers like ferritin (frequently \u003e10,000 ng/mL), C-reactive protein (CRP \u003e100 mg/L), D-dimer, lactate dehydrogenase (LDH), and cytokines such as interleukin-6 (IL-6 \u003e100 pg/mL) and interferon-gamma (IFN-γ) provide supportive evidence, yet these markers lack specificity and are routinely elevated in myriad critical illnesses, complicating attribution to cytokine storm.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7727315/) Practical barriers further impede diagnosis, including the infrequency of cytokine assays in clinical settings due to high costs, limited availability, and prolonged turnaround times, often delaying intervention until organ failure ensues.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8242812/)\n\nDistinguishing cytokine storm from mimics requires contextual evaluation of the inciting event (e.g., infection versus immunotherapy) alongside targeted testing to exclude alternatives.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7727315/) **Sepsis and septic shock** present the most frequent overlap, sharing fever, endothelial leak, and cytokine elevation, but sepsis typically features microbial evidence (e.g., positive blood cultures) and higher procalcitonin or IL-1β levels, with early phases showing subdued T-cell activation compared to the pronounced CD8^+ T-cell proliferation (e.g., \u003e7% CD38^high/HLA-DR^+ CD8^+ T cells via flow cytometry) characteristic of cytokine storm in hemophagocytic contexts.[](https://ashpublications.org/blood/article/137/17/2337/474597/T-cell-activation-profiles-distinguish) This T-cell marker offers high diagnostic utility, with 100% sensitivity and 89% specificity for differentiating such storms from sepsis.[](https://ashpublications.org/blood/article/137/17/2337/474597/T-cell-activation-profiles-distinguish)\n\n**Hemophagocytic lymphohistiocytosis (HLH)** and **macrophage activation syndrome (MAS)**—a rheumatic variant of secondary HLH—closely resemble cytokine storm through shared hyperferritinemia, cytopenias, and coagulopathy, often fulfilling partial HLH-2004 criteria (e.g., splenomegaly, hypofibrinogenemia \u003c150 mg/dL, triglycerides \u003e265 mg/dL, or detectable hemophagocytosis in bone marrow).[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7727315/) HLH diagnostic tools like the HScore (incorporating age, immunosuppression, and cytopenias) or HLH-2004 probability models (\u003e80% for scores ≥169) aid delineation, particularly when genetic defects (e.g., PRF1 mutations) or soluble IL-2 receptor (\u003e7,900 U/mL) are assessed, though these may not apply uniformly to non-HLH cytokine storms.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7727315/) MAS, prevalent in systemic juvenile idiopathic arthritis, emphasizes ferritin:triglyceride ratios \u003e16 for early flagging amid disease flares.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4074772/) Other differentials, such as acute respiratory distress syndrome (ARDS) or iatrogenic reactions in CAR-T therapy, necessitate exclusion via imaging, infection workup, and grading scales like ASTCT for cytokine release syndrome, underscoring the need for multidisciplinary integration to avoid misattribution.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7727315/)\n\n## Treatment Approaches\n\n### Supportive and Symptomatic Management\n\nSupportive management of cytokine storm prioritizes stabilization of vital functions and prevention of irreversible organ damage through intensive care measures, often in an ICU setting, while addressing symptoms such as fever and hypotension. This approach complements efforts to control the underlying trigger and applies across contexts like infections, immunotherapies, and sepsis, where hyperinflammation leads to capillary leak, vasodilation, and tissue hypoxia.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131)[](https://ashpublications.org/blood/article/124/2/188/32896/Current-concepts-in-the-diagnosis-and-management)\n\n![Cytokine release following SARS-CoV-2 infection resulting in ARDS related to COVID-19](./_assets_/Cytokine_release_following_SARS-Cov-2_infection_resulting_in_ARDS_related_to_COVID-19.png)\n\nHemodynamic support begins with intravenous fluid resuscitation to counter hypovolemia from capillary leak and third-spacing, typically using crystalloids, followed by vasopressors such as norepinephrine if hypotension persists despite adequate volume replacement; low-dose vasopressors suffice for grade 2 severity, while high-dose or multiple agents indicate grade 3 or higher.[](https://ashpublications.org/blood/article/124/2/188/32896/Current-concepts-in-the-diagnosis-and-management)[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) In severe cases involving cardiac compromise, such as fulminant myocarditis, mechanical circulatory support like intra-aortic balloon pump (IABP) can elevate systolic blood pressure by over 20 mmHg and reduce heart rate by 20-30 beats per minute, or extracorporeal membrane oxygenation (ECMO) for refractory shock.[](https://www.nature.com/articles/s41392-025-02178-y)\n\nRespiratory support escalates based on hypoxemia severity: low-flow oxygen (less than 40% FiO₂) for mild cases, non-invasive ventilation for moderate distress, and mechanical ventilation with lung-protective strategies for acute respiratory distress syndrome (ARDS), which frequently complicates cytokine storm due to alveolar damage and edema.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131)[](https://ashpublications.org/blood/article/124/2/188/32896/Current-concepts-in-the-diagnosis-and-management) For renal involvement manifesting as acute kidney injury, continuous renal replacement therapy (CRRT) removes excess fluid and inflammatory mediators while supporting electrolyte balance and acid-base homeostasis.[](https://www.nature.com/articles/s41392-025-02178-y)\n\nSymptomatic relief targets fever and discomfort with antipyretics like acetaminophen, avoiding non-steroidal anti-inflammatory drugs due to risks of worsening renal function or bleeding in thrombocytopenic patients.[](https://ashpublications.org/blood/article/124/2/188/32896/Current-concepts-in-the-diagnosis-and-management) Close monitoring of biomarkers, vital signs, and organ function guides escalation, with empiric infection screening to rule out concurrent sepsis, ensuring supportive measures do not delay targeted interventions.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) Outcomes improve when these strategies prevent progression to multi-organ failure, though mortality remains high in grades 3-4 without prompt application.[](https://www.nature.com/articles/s41392-025-02178-y)\n\n### Pharmacological Interventions\n\nCorticosteroids, particularly dexamethasone, represent a cornerstone of pharmacological management for cytokine storm, particularly in severe cases associated with viral infections like COVID-19. The RECOVERY trial, involving over 2,100 hospitalized patients receiving invasive mechanical ventilation or oxygen, demonstrated that dexamethasone at 6 mg daily for up to 10 days reduced 28-day mortality by 35% in ventilated patients (rate ratio 0.65; 95% CI 0.51-0.81) and by 20% in those on oxygen without ventilation (rate ratio 0.80; 95% CI 0.70-0.92), without increasing harm in milder cases. This effect is attributed to suppression of proinflammatory cytokine production and T-cell activation, though high doses risk immunosuppression and secondary infections. Guidelines from bodies like the WHO recommend corticosteroids for patients requiring supplemental oxygen, based on this level 1 evidence, while cautioning against routine use in non-hypoxic cases due to potential delays in viral clearance.00880-7/fulltext)\n\nInterleukin-6 receptor antagonists, such as tocilizumab, target a key mediator of cytokine storm by blocking IL-6 signaling, which drives fever, C-reactive protein elevation, and vascular permeability. In the RECOVERY trial's tocilizumab arm (4,116 patients), a single 8 mg/kg intravenous dose reduced 28-day mortality by 4% absolute risk (31% vs. 35%; rate ratio 0.86; 95% CI 0.77-0.96) in hospitalized COVID-19 patients on oxygen or ventilation, with benefits most pronounced in those with high C-reactive protein (\u003e75 mg/L). Meta-analyses of randomized trials confirm reduced progression to mechanical ventilation (odds ratio 0.72; 95% CI 0.59-0.87) and ICU admission, though efficacy wanes in moderate disease without hypoxia. Similar results apply to CAR-T cell therapy-induced cytokine release syndrome, where tocilizumab is FDA-approved, shortening resolution time by 3-7 days in pivotal trials. Risks include bacterial infections and hepatotoxicity, necessitating monitoring.[](https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15124)\n\nJanus kinase (JAK) inhibitors like baricitinib interrupt downstream signaling of multiple cytokines (e.g., IL-6, IFN-γ) via JAK-STAT pathway blockade, mitigating amplification in cytokine storm. The ACTT-2 trial (1,039 hospitalized COVID-19 patients) showed baricitinib 4 mg daily for up to 14 days, added to remdesivir, accelerated recovery by 1 day (median 7 vs. 8 days; rate ratio 1.16; 95% CI 1.01-1.35) and trended toward lower mortality (5.1% vs. 7.8%), particularly in ventilated subgroups. Meta-analyses indicate probable mortality reduction (risk ratio 0.74; 95% CI 0.60-0.92) in oxygen-dependent patients, independent of viral variants due to host-targeted action. Evidence extends to graft-versus-host disease, where ruxolitinib (a JAK1/2 inhibitor) resolved steroid-refractory cases in 50-60% of patients per phase 3 trials. Adverse events include thrombosis and infections, with contraindications in active malignancy.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8828941/)\n\nInterleukin-1 blockers, such as anakinra, inhibit IL-1-driven inflammation implicated in macrophage activation syndrome-like storms. Observational studies and meta-analyses in severe COVID-19 report 20-30% absolute mortality reductions (e.g., 27% vs. 54% in hyperinflammatory subgroups), with improved PaO2/FiO2 ratios and reduced mechanical ventilation needs in patients with ferritin \u003e3,000 ng/mL or CRP \u003e100 mg/L. However, randomized trials like the SAVE-MORE study showed mixed results, with benefits confined to early hyperinflammation (e.g., 28-day mortality 11.9% vs. 20.6%; hazard ratio 0.55; 95% CI 0.39-0.78) but no overall efficacy in broader cohorts. In hemophagocytic lymphohistiocytosis, anakinra adjunctively lowered ferritin and cytokines in pediatric cases, though etoposide remains primary. Dosing (100 mg subcutaneous daily) requires renal adjustment, with risks of injection-site reactions and neutropenia. Evidence quality varies, with stronger support from real-world data than some underpowered RCTs.[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2803480)[](https://www.sciencedirect.com/science/article/abs/pii/S0953620521000169)\n\nEmerging agents include anti-TNF therapies (e.g., infliximab) and broad immunosuppressants like cyclosporine, but randomized evidence is limited; for instance, infliximab reduced intubation in small COVID-19 trials (18% vs. 37%) yet failed larger validations. Combination regimens (e.g., tocilizumab plus corticosteroids) enhance outcomes in refractory cases, as per cohort studies showing synergistic cytokine suppression, but increase infection risks warranting vigilant monitoring. Selection depends on trigger-specific pathophysiology, biomarker levels (e.g., IL-6 \u003e100 pg/mL favoring anti-IL-6), and contraindications, with no universal first-line beyond supportive care. Ongoing trials explore next-generation inhibitors, emphasizing personalized dosing to balance efficacy against immunosuppression.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7681075/)[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131)\n\n### Controversies and Alternative Perspectives\n\nThe applicability of the \"cytokine storm\" framework to severe COVID-19 has faced scrutiny, with critics arguing that cytokine elevations in affected patients are modest compared to classical storms in conditions like CAR-T cell therapy or acute macrophage activation syndrome, and that persistent lymphopenia rather than hypercytokinemia better characterizes the immunopathology. [](https://pmc.ncbi.nlm.nih.gov/articles/PMC8373392/) This perspective posits that overemphasizing cytokine blockade may divert attention from underlying viral persistence or endothelial dysfunction as primary drivers of organ failure.[](https://journals.lww.com/10.1097/BOR.0000000000000822)\n\nImmunosuppressive treatments, such as corticosteroids, exhibit context-dependent efficacy tied to disease stage; the RECOVERY trial demonstrated a 30% mortality reduction with dexamethasone (6 mg daily for up to 10 days) in hospitalized patients requiring oxygen or ventilation as of June 2020, yet early administration in non-hypoxic or viraemic phases risks prolonging viral replication and delaying recovery by blunting adaptive immunity. [](https://casereports.bmj.com/content/14/2/e241105) Similarly, interleukin-6 inhibitors like tocilizumab yield mixed outcomes: observational data from July 2020 linked it to 45% lower mortality in ventilated COVID-19 patients, and the REMAP-CAP trial (published 2021) confirmed survival benefits in critically ill cases, but randomized trials such as COVACTA (2021) found no significant reduction in ventilator-free days, while subtype analyses indicate potential harm in macrophage activation-like presentations.[](https://www.michiganmedicine.org/health-lab/drug-calms-cytokine-storm-associated-45-lower-risk-dying-among-covid-19-patients)  [](https://pmc.ncbi.nlm.nih.gov/articles/PMC8229480/) These discrepancies highlight risks of secondary bacterial infections and the absence of universal biomarkers to guide timing, with anticytokine approaches failing broadly in non-COVID sepsis trials due to heterogeneous inflammatory phenotypes.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7994048/)\n\nAlternative viewpoints emphasize prophylaxis over reactive suppression, advocating early antiviral agents (e.g., remdesivir or nirmatrelvir-ritonavir initiated within 5-7 days of symptoms) to curtail viral load and preempt escalation to hyperinflammation, as supported by in vitro and observational data showing reduced cytokine induction.[](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.572635/full) Some researchers propose adjunctive non-pharmacological measures, such as mesenchymal stem cell infusions to modulate immunity without broad suppression, though randomized evidence remains limited to small trials demonstrating feasibility in refractory cases as of 2021.00068-6/fulltext) Critics of cytokine-centric paradigms further argue for causal dissection via single-cell transcriptomics to distinguish adaptive from maladaptive responses, cautioning against empirical blockade absent mechanistic validation.[](https://www.nature.com/articles/s41598-021-99291-z)\n\n## Role in Major Diseases\n\n### Cytokine Storm in Viral Infections Including COVID-19\n\n![Cytokine release following SARS-CoV-2 infection resulting in ARDS related to COVID-19](./_assets_/Cytokine_release_following_SARS-Cov-2_infection_resulting_in_ARDS_related_to_COVID-19.png)\n\nCytokine storm manifests in severe viral infections as an dysregulated immune response involving massive release of pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interferons, leading to systemic inflammation, endothelial damage, and multi-organ failure.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7079934/) In highly pathogenic viruses like H5N1 avian influenza, autopsies and clinical data from 1997 outbreaks revealed markedly elevated cytokine levels, with TNF-α concentrations exceeding 500 pg/mL in fatal cases compared to under 10 pg/mL in healthy controls, correlating with diffuse alveolar damage and high lethality rates approaching 60%.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4711683/) Similarly, during the 2009 H1N1 pandemic, severe cases exhibited hypercytokinemia, though less intense than H5N1, contributing to acute respiratory distress syndrome (ARDS) in approximately 10-15% of hospitalized patients.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7832378/)\n\nIn hemorrhagic fever viruses such as Ebola, cytokine storms arise from viral glycoprotein-mediated activation of monocytes and dendritic cells, triggering cascades of IL-6, IL-8, and TNF-α that promote vascular leakage and coagulopathy, with plasma levels of IL-6 reaching over 100 pg/mL in non-survivors versus under 20 pg/mL in survivors during the 2014-2016 West Africa outbreak.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7079934/) SARS-CoV-1 infections during the 2003 epidemic also featured elevated chemokines and cytokines, including IP-10 and MCP-1, associated with lymphopenia and progression to ARDS in fatal cases, mirroring patterns in other coronaviruses.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7832378/) These responses often stem from impaired viral clearance, where pattern recognition receptors like Toll-like receptors overstimulate innate immunity, amplifying inflammation beyond antiviral needs.[](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.659419/full)\n\nFor SARS-CoV-2 causing COVID-19, early 2020 reports from Wuhan described hyperinflammation in intensive care unit (ICU) patients, with IL-6 levels averaging 60-100 pg/mL in severe cases versus 10-20 pg/mL in mild ones, alongside elevations in CRP and ferritin, linking to respiratory failure and mortality rates of 20-30% in ventilated cohorts.[](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.01708/full) However, subsequent analyses questioned the \"cytokine storm\" label, noting that peak cytokine concentrations in COVID-19 (e.g., IL-6 rarely exceeding 200 pg/mL) were substantially lower than in canonical cytokine release syndromes from CAR-T therapy (often \u003e1,000 pg/mL) or bacterial sepsis, suggesting instead a sustained low-grade hyperinflammation driven by persistent antigen and T-cell exhaustion rather than acute explosive release.[](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2767939) Longitudinal studies from 2020-2021 confirmed associations between early IL-6 spikes and poor outcomes, but causality remains debated, as elevations may reflect tissue hypoxia and secondary damage more than primary immunopathology.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7361342/)\n\nEmpirical evidence from interventions underscores this nuance: the RECOVERY trial in 2020-2021 demonstrated that dexamethasone reduced 28-day mortality by 30% in oxygenated COVID-19 patients, implicating glucocorticoid-sensitive inflammation, while tocilizumab (anti-IL-6 receptor) lowered mortality in ventilated patients by 4-10% in subset analyses, yet failed to benefit non-severe cases, indicating cytokine dysregulation contributes selectively to progression rather than universally driving severity.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) Recent 2023-2025 cohort comparisons further reveal that COVID-19 cytokine profiles differ from hemophagocytic lymphohistiocytosis or immunotherapy storms, with lower interferon-gamma and higher IL-10, potentially reflecting viral evasion of type I interferon responses early in infection, allowing later compensatory overdrive.[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2832234) Overall, while cytokine storms exacerbate viral pathogenesis across these infections, their intensity and therapeutic targeting efficacy vary, emphasizing the need for biomarker-stratified approaches over blanket suppression.[](https://www.nature.com/articles/s41392-025-02178-y)\n\n### Cytokine Storm in Immunotherapies and Graft-Versus-Host Disease\n\nCytokine release syndrome (CRS), a form of cytokine storm, arises in immunotherapies due to rapid activation of immune effector cells, leading to excessive cytokine production such as IL-6, IFN-γ, and TNF-α. In chimeric antigen receptor (CAR) T-cell therapies targeting CD19 for B-cell malignancies, CRS incidence ranges from 42% to 100%, with severe cases (grade 3 or higher) occurring in 0% to 46% of patients, typically manifesting within 1-2 weeks post-infusion.[](https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02148-6)[](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.950923/full) Risk factors include high disease burden, elevated baseline inflammatory markers, and product-specific factors like CAR T-cell dose and persistence.[](https://jitc.bmj.com/content/6/1/56) A landmark historical event was the 2006 phase 1 trial of TGN1412, an anti-CD28 monoclonal antibody, where all six healthy volunteers experienced life-threatening CRS characterized by multi-organ failure from massive cytokine release, highlighting risks of polyclonal T-cell activation without antigen specificity.[](https://www.nejm.org/doi/full/10.1056/NEJMoa063842)\n\nCRS also occurs with T-cell engaging bispecific antibodies (e.g., blinatumomab for acute lymphoblastic leukemia or teclistamab for multiple myeloma), though generally milder than in CAR T therapy, with incidence up to 70% but severe events less frequent due to controllable dosing.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11739781/)[](https://ashpublications.org/blood/article/143/16/1565/514709/Consensus-recommendations-on-the-management-of) Management of CRS in these contexts relies on grading via tools like the Lee or ASTCT criteria, with interventions including IL-6 blockade via tocilizumab (effective in 69-100% of severe cases) and corticosteroids for refractory symptoms, alongside supportive care for hypotension and hypoxia.[](https://link.springer.com/article/10.1007/s44272-025-00044-0)[](https://ashpublications.org/blood/article/130/21/2295/36661/Kinetics-and-biomarkers-of-severe-cytokine-release) Prophylactic strategies, such as pre-infusion corticosteroids, reduce incidence in high-risk settings.[](https://www.sciencedirect.com/science/article/pii/S1083879118315799)\n\nIn graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation, cytokine storm contributes to acute GVHD pathophysiology through a two-phase process: initial host tissue damage from conditioning regimens (chemotherapy/radiation) releases damage-associated molecular patterns and cytokines (e.g., IL-1, TNF-α), promoting donor T-cell activation; subsequent lipopolysaccharide translocation from gut barrier disruption amplifies systemic inflammation via a \"cytokine storm\" involving IFN-γ and other effectors.[](https://ashpublications.org/blood/article/95/9/2754/125533/The-primacy-of-the-gastrointestinal-tract-as-a)[](https://www.ncbi.nlm.nih.gov/books/NBK538235/) Acute GVHD incidence post-transplant is 30-50% in matched settings, rising with mismatches, with cytokine dysregulation driving skin, liver, and gastrointestinal involvement.[](https://emedicine.medscape.com/article/429037-overview) Chronic GVHD, affecting 30-70% of long-term survivors, features persistent cytokine mediation (e.g., IL-21, BAFF), sustaining B-cell and fibrotic responses.[](https://www.jci.org/articles/view/90593) Treatment targets include corticosteroids as first-line (response rates 50-70%), JAK inhibitors like ruxolitinib for steroid-refractory cases (improving symptoms in 50-60%), and cytokine-specific agents, though prophylaxis with calcineurin inhibitors and methotrexate reduces overall GVHD risk by 20-40%.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8417310/)[](https://www.clinmedres.org/content/2/4/243) Overlap exists with immunotherapy CRS, as both involve T-cell hyperactivation, informing shared therapeutic approaches like IL-6 inhibition in severe GVHD.[](https://www.astctjournal.org/article/S1083-8791%2805%2900846-3/fulltext)\n\n### Cytokine Storm in Autoimmune and Other Conditions\n\nMacrophage activation syndrome (MAS), a severe complication of autoimmune and autoinflammatory diseases such as systemic juvenile idiopathic arthritis (sJIA) and systemic lupus erythematosus (SLE), exemplifies cytokine storm through uncontrolled macrophage and T-cell activation, leading to hemophagocytosis and multi-organ failure.[](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.00119/full) This hyperinflammatory state features markedly elevated levels of pro-inflammatory cytokines, including interleukin-6 (IL-6), interleukin-18 (IL-18), tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ), which amplify immune dysregulation and tissue damage.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4074772/) In sJIA-associated MAS, serum IL-18 concentrations often exceed 100,000 pg/mL, far surpassing levels in uncomplicated disease, correlating with disease severity and hemophagocytic activity.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131)\n\nIn SLE, MAS occurs in approximately 3-7% of cases, particularly in pediatric-onset disease, where it triggers a cytokine storm superimposed on baseline autoimmunity, with rapid progression to disseminated intravascular coagulation and hepatic dysfunction if untreated.[](https://link.springer.com/chapter/10.1007/978-3-031-59815-9_24) Elevated cytokines such as IL-6 and IL-10 in SLE-MAS patients reflect a shift from adaptive to innate immune dominance, driven by impaired natural killer cell cytotoxicity and persistent antigenic stimulation from immune complexes.[](https://pubmed.ncbi.nlm.nih.gov/39117826/) Case reports document ferritin levels surpassing 10,000 ng/mL alongside cytokine surges, underscoring MAS as a diagnostic overlap between SLE flares and secondary hemophagocytic lymphohistiocytosis (HLH).[](https://www.cureus.com/articles/258388-unleashing-the-cytokine-storm-a-case-of-macrophage-activation-syndrome-in-systemic-lupus-erythematosus)\n\nSecondary HLH in autoimmune contexts, including adult-onset Still's disease and rheumatoid arthritis (RA), similarly involves cytokine storm as a core pathogenic feature, with IFN-γ overproduction from activated T cells and macrophages perpetuating a feedback loop of inflammation.[](https://pubmed.ncbi.nlm.nih.gov/35819695/) In RA, while chronic synovial cytokine elevation (e.g., TNF-α and IL-6) contributes to joint erosion, acute cytokine storms are rarer but can emerge in treatment-refractory cases or overlaps with MAS, marked by systemic symptoms and elevated soluble IL-2 receptor levels exceeding 10,000 U/mL.[](https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.40071) Diagnostic criteria for HLH-2004, adapted for autoimmune triggers, require at least five of eight features, including hyperferritinemia (\u003e500 ng/mL) and cytopenias, often validated by cytokine profiling in these settings.[](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-024-01621-x)\n\nBeyond rheumatic diseases, cytokine storms arise in other autoimmune conditions like autoinflammatory syndromes, where genetic defects in cytokine regulation (e.g., IL-1 pathway dysregulation) provoke episodic hyperinflammation akin to familial HLH.[](https://pubmed.ncbi.nlm.nih.gov/34681901/) These events differ from infectious triggers by lacking external pathogens, relying instead on intrinsic immune imbalances that sustain cytokine release without resolution, as evidenced by transcriptomic studies showing persistent macrophage polarization.[](https://www.nature.com/articles/s41584-020-00571-1) Early recognition via biomarkers like soluble CD163 and neopterin aids differentiation from disease flares, emphasizing the need for targeted cytokine blockade to mitigate mortality rates, which approach 20-30% in severe autoimmune-associated cases.00180-6/fulltext)\n\n## Historical Development\n\n### Pre-1990s Observations\n\nThe pathological consequences of dysregulated cytokine release were initially observed in the context of endotoxic shock during the 1970s and 1980s, predating the formal recognition of cytokine storms. In 1975, Carswell et al. identified a serum factor, later named tumor necrosis factor (TNF), in mice treated with bacterial endotoxin, which induced hemorrhagic necrosis in transplanted tumor cells and mimicked aspects of systemic toxicity from gram-negative infections.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3380349/) This factor was purified and cloned by 1984, revealing its potent proinflammatory properties, including induction of fever, endothelial activation, and organ dysfunction similar to clinical septic shock.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5021902/)\n\nFurther experiments in the mid-1980s established TNF as a central mediator of endotoxin-induced lethality. In 1985, TNF was shown to be identical to cachectin, a macrophage-derived protein causing cachexia and metabolic derangements in chronic inflammatory states, with elevated levels observed in models of bacterial sepsis.[](https://centennial.rucares.org/index.php?page=Tumor_Necrosis_Factor) By 1986, administration of recombinant TNF reproduced the hemodynamic collapse, hypotension, and multiorgan failure characteristic of endotoxemia in animal models.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11373197/) Neutralization studies provided causal evidence: in 1987, Tracey et al. demonstrated that anti-TNF monoclonal antibodies prevented death from septic shock in primates bacteremic with *Escherichia coli*, highlighting TNF's role in amplifying vascular permeability and coagulopathy.[](https://www.nature.com/articles/330662a0) These findings underscored a feedback loop where initial endotoxin exposure triggered macrophage cytokine release, escalating to self-sustaining hyperinflammation.\n\nIn graft-versus-host disease (GVHD), pre-1990s research documented analogous hyperinflammatory cascades following allogeneic bone marrow transplantation. As early as the 1960s, acute GVHD was clinically observed as donor T-cell mediated tissue destruction, but 1980s rodent models revealed cytokine-driven amplification, with TNF and interleukin-1 (IL-1) promoting endothelial damage and epithelial apoptosis in gut and skin.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4102708/) Studies in lethally irradiated mice showed that donor lymphocyte infusion led to rapid elevations in serum TNF, correlating with lethality from bowel inflammation and secondary bacterial translocation, independent of direct cytotoxicity.[](https://www.sciencedirect.com/science/article/pii/S0006497120640897) This cytokine-mediated escalation was noted to exacerbate conditioning regimen toxicity, such as from total body irradiation, by sustaining proinflammatory signaling in target organs.[](https://www.astctjournal.org/article/S1083-8791%2899%2970011-X/pdf)\n\nEarly observations in other contexts, such as viral hemorrhagic fevers and severe bacterial infections, similarly pointed to unchecked cytokine activity without invoking the later \"storm\" terminology. For instance, 1980s assays in dengue shock syndrome detected high circulating TNF levels preceding vascular leak and hypotension, suggesting a common mechanism of immune overactivation.[](https://link.springer.com/article/10.1007/s00281-017-0640-2) These pre-molecular insights, derived from bioassays and limited immunoassays, emphasized causal links between microbial triggers, macrophage activation, and fatal systemic inflammation, laying groundwork for understanding cytokine dysregulation as a driver of mortality in critical illnesses.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11847631/)\n\n### Coining of the Term and Early Research (1990s-2000s)\n\nThe term \"cytokine storm\" was first coined in 1993 by James L. Ferrara and colleagues to characterize the explosive release of proinflammatory cytokines, with interleukin-1 (IL-1) playing a pivotal effector role, in acute graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation.[](https://pubmed.ncbi.nlm.nih.gov/8442093/) Ferrara et al. described this as a cascading amplification of cytokine production by donor T cells and host tissues, leading to widespread endothelial activation, tissue necrosis, and multiorgan failure, distinguishing it from mere immune activation by its self-sustaining, storm-like intensity.[](https://pubmed.ncbi.nlm.nih.gov/8442093/) This framing drew on emerging evidence of cytokine dysregulation, where GVHD manifestations such as skin rash, diarrhea, and liver dysfunction were attributed not primarily to direct T-cell cytotoxicity but to secondary inflammatory mediators like IL-1 and tumor necrosis factor-alpha (TNF-α).[](https://www.sciencedirect.com/science/article/pii/095279159390139J)\n\nThroughout the 1990s, research solidified the cytokine storm model in GVHD through clinical correlations and murine models, revealing peak elevations of TNF-α, IL-1, and interferon-gamma (IFN-γ) within days of transplantation onset, correlating with grade III-IV acute GVHD incidence rates exceeding 50% in mismatched donors.[](https://pubmed.ncbi.nlm.nih.gov/8240742/) Preclinical studies demonstrated that neutralizing IL-1 via receptor antagonists reduced lethality by 40-60% in lethally irradiated mice, while anti-TNF monoclonal antibodies ameliorated gut and liver pathology, underscoring cytokines' causal role over alloantigen mismatch alone.[](https://pubmed.ncbi.nlm.nih.gov/8442093/) These findings prompted early clinical explorations, including pilot trials of soluble TNF receptors, which showed modest reductions in GVHD-related mortality but highlighted challenges in timing and specificity amid the storm's rapidity.[](https://www.sciencedirect.com/science/article/pii/095279159390139J)\n\nBy the early 2000s, the paradigm extended to infectious contexts, particularly severe viral pneumonias, where autopsy data from H5N1 avian influenza cases (1997-2004 outbreaks) documented hypercytokinemia with IL-6 levels up to 100-fold above norms, driving diffuse alveolar damage and ARDS mortality rates near 60%.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9310545/) This application reframed cytokine storms as a maladaptive host response amplifying pathogen clearance into systemic collapse, influencing sepsis models where similar TNF-α/IL-1 surges predicted 30-day mortality odds ratios of 3-5 in Gram-negative infections.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7079934/) Such insights spurred targeted cytokine blockade trials, though mixed outcomes revealed context-dependent drivers, with GVHD storms favoring T-cell origins versus infection-triggered innate responses.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3294426/)\n\n### Evolution During Pandemics and Recent Insights (2010s-2025)\n\n![Cytokine release following SARS-CoV-2 infection resulting in ARDS related to COVID-19](./_assets_/Cytokine_release_following_SARS-Cov-2_infection_resulting_in_ARDS_related_to_COVID-19.png)\nDuring the 2009-2010 H1N1 influenza pandemic, research identified cytokine storms as a key factor in severe and fatal cases, particularly among young adults. Autopsy studies revealed that peak viral loads in lungs correlated with markedly elevated levels of proinflammatory cytokines such as IL-6 and TNF-α, contributing to diffuse alveolar damage and rapid deterioration.[](https://www.cidrap.umn.edu/h1n1-2009-pandemic-influenza/study-shows-cytokine-storm-fatal-2009-h1n1-cases) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC3192778/) Analysis of severe pneumonia cases showed hyperactivation of cytokines including IL-6, IL-8, and MCP-1, which correlated with clinical severity, prolonged viral shedding, and higher mortality, distinguishing them from milder infections.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3192778/) [](https://academic.oup.com/cid/article/50/6/850/418325) These findings advanced understanding of cytokine dysregulation in viral pandemics, prompting early explorations of immunomodulatory therapies, though widespread application lagged until later outbreaks.\n\nThe 2019-2020 COVID-19 pandemic markedly accelerated research on cytokine storms, establishing them as a central driver of acute respiratory distress syndrome (ARDS) and multi-organ failure in severe cases. Elevated circulating levels of IL-6, IL-1β, TNF, and IP-10 were consistently observed in critically ill patients, with cytokine profiles differing from those in pandemic influenza by including higher Th2-associated mediators like IL-4 and IL-17A.[](https://www.nejm.org/doi/full/10.1056/NEJMra2026131) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC9422807/) Comparisons with H1N1 revealed shared hyperinflammation but unique COVID-19 features, such as impaired type I interferon responses and neutrophil extracellular traps exacerbating lung injury.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9422807/) This led to rapid clinical trials demonstrating benefits from IL-6 inhibitors like tocilizumab and corticosteroids such as dexamethasone, reducing mortality in ventilated patients by modulating excessive immune activation without broadly suppressing antiviral responses.30628-0/fulltext) [](https://www.nature.com/articles/s41392-025-02178-y)\n\nPost-2020 insights have refined mechanistic models, identifying overactivation of the JAK/STAT pathway and PANoptosis—a proinflammatory cell death program—as amplifiers of cytokine release in COVID-19 and related syndromes.[](https://www.nature.com/articles/s41392-025-02178-y) In December 2024, studies uncovered novel triggers, including SARS-CoV-2-induced mitochondrial dysfunction in immune cells, which propagates hyperinflammation via altered energy metabolism and cytokine signaling cascades.[](https://www.hopkinsmedicine.org/news/newsroom/news-releases/2024/12/a-cause-of-hyperinflammatory-response-in-lethal-covid19-identified) [](https://news.weill.cornell.edu/news/2024/12/study-details-surprising-biological-mechanisms-underlying-severe-covid-19) By 2025, bibliometric analyses highlighted a surge in research hotspots, emphasizing targeted interventions like JAK inhibitors and cytokine-neutralizing nanosponges for pandemic preparedness, while underscoring persistent challenges in early detection via biomarkers.[](https://www.sciencedirect.com/science/article/pii/S240584402406986X) [](https://www.nature.com/articles/s41392-025-02178-y) These developments have shifted focus from blanket immunosuppression to precision modulation, informed by empirical outcomes from COVID-19's scale.\n\n## Ongoing Research and Future Directions\n\n### Recent Discoveries (2023-2025)\n\nIn 2024, researchers identified a vagal sensory neuron-to-caudal nucleus of the solitary tract (cNST) neural circuit that bidirectionally controls systemic inflammation, with activation of dopamine beta-hydroxylase (DBH)-expressing cNST neurons suppressing pro-inflammatory cytokines such as IL-1β by approximately 70% while elevating anti-inflammatory IL-10 up to tenfold in lipopolysaccharide-challenged mice.[](https://www.nature.com/articles/s41586-024-07469-y) This circuit's silencing exacerbated cytokine release, increasing IL-1β levels from 200 to 800 pg/ml and reducing IL-10 from 750 to 250 pg/ml, whereas chemogenetic stimulation protected against lethal endotoxemia (90% survival rate) and dextran sulfate sodium-induced colitis by modulating vagal TRPA1 neurons for anti-inflammatory effects.[](https://www.nature.com/articles/s41586-024-07469-y) Single-cell RNA sequencing and calcium imaging confirmed cytokine-responsive vagal afferents projecting to cNST, highlighting a brain-body axis for potential neuromodulatory interventions in sepsis and autoimmune cytokine storms.[](https://www.nature.com/articles/s41586-024-07469-y)\n\nComputational protein design yielded de novo miniproteins in 2024 that antagonize key cytokine storm inducers IL-6 and IL-1β by binding their receptors with high affinity, such as IL-6Rmb10 (KD 300 pM) shifting IL-6 EC50 by 74.7-fold and IL-1Rmb81 (IC50 2.8 nM) reducing IL-1β-induced damage in human cardiac organoids.[](https://www.nature.com/articles/s41467-024-50919-4) Developed via Rosetta docking of scaffolds to receptor interfaces, followed by yeast display screening and X-ray validation showing atomic-level fit, these ≤65-residue binders blocked signaling in bone marrow-derived cells and preserved organoid function against SARS-CoV-2-mimicking inflammation without off-target effects on related pathways.[](https://www.nature.com/articles/s41467-024-50919-4) Their short half-life and thermostability position them as tunable alternatives to monoclonal antibodies for acute cytokine storms in infections or immunotherapies.[](https://www.nature.com/articles/s41467-024-50919-4)\n\nA short-acting anti-IL-6 receptor monoclonal antibody, reported in early 2024, transiently blocks IL-6 signaling to inhibit hypoxia-inducible factor-1α (HIF1α) activation, thereby stabilizing vascular endothelium and curbing leakage in sepsis and burn models without the sustained immunosuppression of long-acting inhibitors. Preclinical data showed reduced tissue inflammation and improved survival in cytokine release syndrome akin to COVID-19 or acute respiratory distress, emphasizing targeted, time-limited intervention to preserve immune competence. Concurrently, a multi-institutional analysis pinpointed overactivation of immune response genes alongside renin-angiotensin-aldosterone system (RAAS) dysregulation as the precipitating trigger for COVID-19 cytokine storms, correlating this dual pathway with organ failure and elevated mortality in severe cases.[](https://scitechdaily.com/johns-hopkins-scientists-uncover-hidden-trigger-behind-covid-19s-deadly-cytokine-storm/)\n\nIn 2025, macrophage studies demonstrated that elevating eukaryotic initiation factor 2 alpha (eIF2α) phosphorylation disrupts transcription-translation coupling, selectively inhibiting cytokine hyperproduction during inflammatory challenges and averting storm-like responses.[](https://www.sciencedirect.com/science/article/abs/pii/S1567576924024871) This mechanism, validated in vitro, underscores integrated stress response pathways as novel checkpoints for therapeutic modulation in sepsis and viral pathologies.[](https://www.sciencedirect.com/science/article/abs/pii/S1567576924024871)\n\n### Emerging Therapies and Prevention Strategies\n\nMonoclonal antibodies targeting novel inflammatory mediators represent a key emerging therapy for mitigating cytokine storms. In preclinical murine models of sepsis induced by *Pseudomonas aeruginosa* or lipopolysaccharide, a humanized antibody against citrullinated histone H3 (hCitH3-mAb), administered at 20 mg/kg, disrupted a TLR2-calcium-PAD2 feedback loop that drives neutrophil extracellular trap (NET) formation and pyroptosis, resulting in significantly reduced levels of pro-inflammatory cytokines IL-6 and IL-1β, lower bacterial loads in lungs, spleen, and liver, and enhanced survival rates.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12343807/) Elevated serum CitH3 levels in human septic patients correlate with disease severity, supporting its role as a therapeutic target.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12343807/)\n\nA separate humanized monoclonal antibody, developed to address sepsis-induced immune dysregulation, blocks excessive cytokine release while restoring macrophage function and preventing organ damage, such as lung injury, in mouse models without broadly suppressing adaptive immunity; as of August 2025, it has advanced to funded clinical trials at U.S. institutions, with preclinical data confirming safety and efficacy in halting storm progression.[](https://doi.org/10.1038/s41467-025-62788-6)\n\nSmall-molecule inhibitors of the JAK-STAT pathway, including ruxolitinib (a JAK1/2 inhibitor), have gained traction for cytokine release syndrome (CRS) in CAR-T cell therapies and hemophagocytic lymphohistiocytosis (HLH), where they attenuate signaling from multiple cytokines like IL-6, IFN-γ, and TNF-α; recent refinements emphasize selective inhibition to balance efficacy against infection risks, with phase 2/3 trials demonstrating reduced refractory cases.[](https://www.nature.com/articles/s41392-025-02178-y) Anakinra, an IL-1 receptor antagonist, serves as an adjunct for steroid-resistant CRS, controlling inflammation and neurotoxicity in clinical settings.[](https://www.nature.com/articles/s41392-025-02178-y)\n\nNovel delivery systems, such as cytokine nanosponges—nanoparticles coated with macrophage membranes—have shown preclinical promise in neutralizing excess cytokines in HLH mouse models, alleviating symptoms without systemic immunosuppression.[](https://www.nature.com/articles/s41392-025-02178-y) Mesenchymal stem cells (MSCs) exert immunomodulatory effects by polarizing macrophages toward an anti-inflammatory M2 phenotype and suppressing T-cell proliferation, with over 1,000 registered trials exploring their use in graft-versus-host disease and viral ARDS as of 2025, though outcomes vary due to cell sourcing heterogeneity.[](https://www.nature.com/articles/s41392-025-02178-y)\n\nPrevention strategies prioritize biomarker-driven risk stratification, using metrics like the EASIX score, serum IL-6, ferritin, and CD8+ T-cell counts to identify at-risk patients early in conditions such as sepsis or immunotherapy.[](https://www.nature.com/articles/s41392-025-02178-y) In CAR-T protocols, prophylactic tocilizumab (IL-6 blockade, 8 mg/kg IV up to 4 doses) or anakinra reduces CRS incidence and severity, particularly in high-tumor-burden cases.[](https://www.nature.com/articles/s41392-025-02178-y) For viral infections, rapid pathogen detection and initiation of antivirals within 1 hour, combined with cytokine monitoring, prevents escalation to storm; blood purification techniques, like β2-microglobulin adsorption columns, offer adjunctive support by depleting circulating IL-6 and TNF in septic patients.[](https://www.nature.com/articles/s41392-025-02178-y) These approaches underscore the need for personalized timing, as indiscriminate early immunosuppression can exacerbate infections.[](https://www.nature.com/articles/s41392-025-02178-y)"])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761886723256,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"Cytokine Storm | New England Journal of Medicine\",\"description\":\"Dec 2, 2020 · Cytokine storm and cytokine release syndrome are life-threatening systemic inflammatory syndromes involving elevated levels of circulating cytokines and immune ...\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMra2026131\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"Cytokine Storm—Definition, Causes, and Implications - PMC\",\"description\":\"It is usually understood to mean an overwhelming immune response characterized by the release of cytokines, including interleukins, interferons, chemokines, ...Missing:  peer- | Show results with:peer-\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9570384/\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"The 'Cytokine Storm': molecular mechanisms and therapeutic ...\",\"description\":\"Cytokine storm syndrome has generally been described as a collection of clinical manifestations resulting from an overactivated immune system.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9310545/\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"Cytokine Storm - PMC - PubMed Central\",\"description\":\"Dec 3, 2020 · Cytokine storm can occur as a result of inappropriate recognition (e.g., in hypersensitivity) or ineffective recognition with immune evasion (e ...\u003c|separator|\u003e\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7727315/\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"Cytokine storms in infectious diseases - PMC - PubMed Central\",\"description\":\"Jul 3, 2017 · Elevated cytokine and chemokine production has been continuously associated with poor clinical outcome and pathogenesis during respiratory viral ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7079934/\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"Targeting the “Cytokine Storm” for Therapeutic Benefit - PMC\",\"description\":\"One of the most studied examples of an organism that can cause cytokine storms is influenza A virus, in particular the pandemic subtypes. For example, the ...Missing:  consequences | Show results with:consequences\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3592351/\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"An inflammatory cytokine signature predicts COVID-19 severity and ...\",\"description\":\"Aug 24, 2020 · We found that high serum IL-6, IL-8 and TNF-α levels at the time of hospitalization were strong and independent predictors of patient survival.\",\"url\":\"https://www.nature.com/articles/s41591-020-1051-9\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"Is a “Cytokine Storm” Relevant to COVID-19? - JAMA Network\",\"description\":\"Jun 30, 2020 · Broadly speaking, it denotes a hyperactive immune response characterized by the release of interferons, interleukins, tumor-necrosis factors, ...Missing:  reviewed | Show results with:reviewed\",\"url\":\"https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2767939\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"Deep insight into cytokine storm: from pathogenesis to treatment\",\"description\":\"Apr 16, 2025 · Cytokine storm (CS) is a severe systemic inflammatory syndrome characterized by the excessive activation of immune cells and a significant ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12000524/\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"Are all cytokine storms the same? - PMC - PubMed Central - NIH\",\"description\":\"Jan 8, 2021 · Cytokine storm results from massive pro-inflammatory cytokine release and imbalance and can cause severe symptoms or death following cancer ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7791954/\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"Cytokine Storms: Understanding COVID-19 - ScienceDirect.com\",\"description\":\"Jul 14, 2020 · The elevated circulating levels of cytokines associated with a variety of infectious and immune-mediated conditions are frequently termed a cytokine storm.\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S1074761320302727\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"Cytokine Storm: The Primary Determinant for the Pathophysiological ...\",\"description\":\"When the virus invades the body, it can cause an imbalance in the immune system that may result in a cytokine storm. COVID-19 patients deteriorate over a short ...Missing:  definition | Show results with:definition\",\"url\":\"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.589095/full\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"Deep insight into cytokine storm: from pathogenesis to treatment\",\"description\":\"Apr 16, 2025 · Cytokine storm (CS) is a severe systemic inflammatory syndrome characterized by the excessive activation of immune cells and a significant increase in ...\",\"url\":\"https://www.nature.com/articles/s41392-025-02178-y\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"Cytokine release syndrome in severe COVID-19: interleukin-6 ...\",\"description\":\"IL-6 plays a central role in the cytokine storm. It is a multi-effective cytokine with both anti-inflammatory and pro-inflammatory effects. There are three main ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7118634/\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"IL-6 in inflammation, autoimmunity and cancer - PubMed Central - NIH\",\"description\":\"Pro-inflammatory cytokines such as IL-1β, tumor necrosis factor alpha (TNFα) and IL-6 play crucial roles in inflammation. Among them, IL-6 is a major player in ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7799025/\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"Understanding the cytokine storm during COVID-19\",\"description\":\"These cytokines, specifically TNF and IL-17, act together on the vascular endothelium and promote local thrombosis in small and large vessels (9). At the same ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7431332/\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"Cytokine Storm - an overview | ScienceDirect Topics\",\"description\":\"TNF-α and TNF-β, produced by macrophages and activated T cells, respectively, are key cytokines involved in response to acute viral infections, including ...\",\"url\":\"https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/cytokine-storm\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"IL1β, IL-6, and TNF-α cytokines cooperate to modulate a ... - NIH\",\"description\":\"Increases in proinflammatory cytokines, including IL-1β, IL-6, and TNF-α, are indicators of illness progression and an approaching cytokine storm. Additionally, ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10289607/\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"Cytokine Storm in COVID-19: Exploring IL-6 Signaling and Cytokine ...\",\"description\":\"To protect the host from SARS-CoV-2 infection, alongside IL-6 and IL-1, TNF-α is another key cytokine involved in orchestrating proinflammatory responses and ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11547016/\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"The Impact of Cytokine Storms on Severe Infectious Diseases ...\",\"description\":\"May 5, 2025 · Cytokine storm is a life-threatening immune reaction contributing to the severity of various infectious diseases such as COVID-19, sepsis, Ebola, and Dengue.\u003c|separator|\u003e\",\"url\":\"https://jpmsonline.com/article/the-impact-of-cytokine-storms-on-severe-infectious-diseases-progression-a-narrative-review-720/\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"Quantification of Cytokine Storms During Virus Infections - PMC\",\"description\":\"For example, the H5N1 influenza virus sets off a cytokine storm, including but not limited to interferon (IFN)-β, interleukin (IL)-6, and interferon-inducible ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8165266/\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"Editorial: From Pathogenic Infections to Inflammation and Disease\",\"description\":\"Pathogens causing systemic inflammatory response syndrome associated to cytokine storms include many bacterial infections, such as those caused by the group A ...Editorial · Concluding Remarks\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2021.827151/full\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell ...\",\"description\":\"Cytokine release syndrome (CRS), resulting from rapid immune activation induced by CAR-Ts, is the most significant treatment-related toxicity.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/30586620/\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"Mechanisms of cytokine release syndrome and neurotoxicity of CAR ...\",\"description\":\"Nov 18, 2021 · CRS is the most common toxicity related to CAR T-cell therapy, with an incidence of 42–100%, and 0–46% of patients develop severe CRS after CAR ...\",\"url\":\"https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02148-6\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"The critical impacts of cytokine storms in respiratory disorders\",\"description\":\"May 15, 2024 · T-cell stimulation triggers iatrogenic cytokine storm, which is propagated by immune cell activation. CD28 receptor is a secondary receptor ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S2405844024058006\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"Cytokine dysregulation as a mechanism of graft versus host disease\",\"description\":\"Most of the clinical manifestations of GVHD may in fact be due to the dysregulated production of cytokines by T cells and other inflammatory cells.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/8240742/\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"The cytokine storm and acute graft-versus-host disease (aGVHD ...\",\"description\":\"The use of RIC regimens has modified the natural history of transplant-related complications, especially aGVHD. The aim of this study was to investigate the ...\",\"url\":\"https://www.astctjournal.org/article/S1083-8791%2805%2900846-3/fulltext\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"Cytokine Storms: Understanding COVID-19 - PMC - PubMed Central\",\"description\":\"Jun 28, 2020 · A hallmark of a cytokine storm is persistent fever and non-specific constitutional symptoms (weight loss, joint and muscle pain, fatigue, ...\u003c|separator|\u003e\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7321048/\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"Harnessing the immune system to overcome cytokine storm and ...\",\"description\":\"Oct 15, 2020 · Being a novel virus, there has been a steep learning curve about its microbiology, host interactions, mechanism of immune dysregulation in ...\",\"url\":\"https://virologyj.biomedcentral.com/articles/10.1186/s12985-020-01415-w\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"Cytokine Storm: The Primary Determinant for the Pathophysiological ...\",\"description\":\"When the virus invades the body, it can cause an imbalance in the immune system that may result in a cytokine storm. COVID-19 patients deteriorate over a short ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8115911/\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"Potential Pathophysiological Mechanisms Underlying Multiple ...\",\"description\":\"Il-6, which is known as the eye of the cytokine storm, performs a critical part in inflammatory and immunological responses. IL-6 transmits signals and exerts ...\u003c|separator|\u003e\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9007670/\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"Cytokine storm associated coagulation complications in COVID-19 ...\",\"description\":\"IFN-γ may cause fever with chills, headaches, fatigue and dizziness. TNF-α may also exhibit flu-like symptoms along with cardiomyopathy, vascular leakage, ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8074652/\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"COVID-19 infection: an overview on cytokine storm and related ...\",\"description\":\"May 26, 2022 · Cytokine storm is defined as acute overproduction and uncontrolled release of pro-inflammatory markers, both locally and systemically. The ...Missing:  peer- | Show results with:peer-\",\"url\":\"https://virologyj.biomedcentral.com/articles/10.1186/s12985-022-01814-1\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"Critical roles of cytokine storm and secondary bacterial infection in ...\",\"description\":\"Kidney injury at admission, cytokine storm, and ARDS were significant influence factors of AKI development in COVID‐19 patients. More intriguingly, these ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8426723/\",\"favicon\":\"\"},{\"id\":\"35\",\"title\":\"Biomarkers of cytokine storm as red flags for severe and fatal COVID ...\",\"description\":\"Jun 29, 2021 · This study concluded that the cytokine storm is associated with COVID-19 severity, likely through increased pulmonary pathology, T cell ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8241122/\",\"favicon\":\"\"},{\"id\":\"36\",\"title\":\"Point‐of‐care detection of cytokines in cytokine storm management ...\",\"description\":\"This review aims to summarize and discuss the latest technologies for detection of cytokines with a focus on POCT.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8242812/\",\"favicon\":\"\"},{\"id\":\"37\",\"title\":\"T-cell activation profiles distinguish hemophagocytic ...\",\"description\":\"Apr 29, 2021 · We conclude that the cytokine storm of HLH is marked by distinctive T-cell activation whereas early sepsis is not, and that these 2 syndromes ...\",\"url\":\"https://ashpublications.org/blood/article/137/17/2337/474597/T-cell-activation-profiles-distinguish\",\"favicon\":\"\"},{\"id\":\"38\",\"title\":\"MACROPHAGE ACTIVATION SYNDROME AND CYTOKINE ...\",\"description\":\"There are no validated diagnostic criteria for MAS, and early diagnosis is often difficult due to similarities with a SJIA flare and/or sepsis-like syndromes.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4074772/\",\"favicon\":\"\"},{\"id\":\"39\",\"title\":\"Current concepts in the diagnosis and management of cytokine ...\",\"description\":\"This report presents a novel system to grade the severity of CRS in individual patients and a treatment algorithm for management of CRS based on severity.\",\"url\":\"https://ashpublications.org/blood/article/124/2/188/32896/Current-concepts-in-the-diagnosis-and-management\",\"favicon\":\"\"},{\"id\":\"40\",\"title\":\"Efficacy and safety of tocilizumab versus standard care/placebo in ...\",\"description\":\"Oct 29, 2021 · A previous meta-analysis from observational studies has shown that tocilizumab significantly reduces the risk of mortality, need for ventilation ...\",\"url\":\"https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15124\",\"favicon\":\"\"},{\"id\":\"41\",\"title\":\"The Efficacy and Safety of Janus Kinase Inhibitors for Patients With ...\",\"description\":\"Jan 27, 2022 · Baricitinib probably decreases mortality in hospitalized adult patients with COVID-19, especially for patients who required supplemental oxygen ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8828941/\",\"favicon\":\"\"},{\"id\":\"42\",\"title\":\"Efficacy and Safety of Anakinra Plus Standard of Care for Patients ...\",\"description\":\"Apr 7, 2023 · This randomized clinical trial assesses the efficacy and safety of anakinra vs standard of care alone in patients with severe COVID-19 ...\",\"url\":\"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2803480\",\"favicon\":\"\"},{\"id\":\"43\",\"title\":\"Anakinra for patients with COVID-19: a meta-analysis of non ...\",\"description\":\"Anakinra is a recombinant form of IL-1 receptor antagonist. •. Several studies on anakinra in COVID-19 reported positive effects on mortality. •.\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0953620521000169\",\"favicon\":\"\"},{\"id\":\"44\",\"title\":\"Immunopathogenesis and treatment of cytokine storm in COVID-19\",\"description\":\"In this review, we provide an overview of cytokine storm in COVID-19 and treatments currently being used to address it.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7681075/\",\"favicon\":\"\"},{\"id\":\"45\",\"title\":\"Is severe COVID-19 a cytokine storm syndrome - PubMed Central\",\"description\":\"The concept of cytokine storm in COVID-19 has been criticised, given the lack of clear definition and relatively modest cytokinaemia (which may be necessary for ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8373392/\",\"favicon\":\"\"},{\"id\":\"46\",\"title\":\"Is severe COVID-19 a cytokine storm syndrome - LWW\",\"description\":\"The aetiopathogenesis of cytokine storms is not fully understood but is thought to occur as a result of inappropriate recognition (e.g., autoinflammatory ...\u003c|separator|\u003e\",\"url\":\"https://journals.lww.com/10.1097/BOR.0000000000000822\",\"favicon\":\"\"},{\"id\":\"47\",\"title\":\"Steroid harms if given early in COVID-19 viraemia - BMJ Case Reports\",\"description\":\"We report a case of wrong timing of dexamethasone use in COVID-19 management resulting in delayed recovery.\",\"url\":\"https://casereports.bmj.com/content/14/2/e241105\",\"favicon\":\"\"},{\"id\":\"48\",\"title\":\"Drug That Calms 'Cytokine Storm' Associated with 45% Lower Risk ...\",\"description\":\"Jul 13, 2020 · Critically ill COVID-19 patients on ventilators who got tocilizumab in an observational study were 45% less likely to die.Missing:  controversies | Show results with:controversies\",\"url\":\"https://www.michiganmedicine.org/health-lab/drug-calms-cytokine-storm-associated-45-lower-risk-dying-among-covid-19-patients\",\"favicon\":\"\"},{\"id\":\"49\",\"title\":\"Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 ...\",\"description\":\"Tocilizumab therapy in patients with COVID-19 and CRS was associated with increased mortality, while in MAS patients, it contributed to reduced mortality.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8229480/\",\"favicon\":\"\"},{\"id\":\"50\",\"title\":\"New Decade, Old Debate: Blocking the Cytokine Pathways in ...\",\"description\":\"Mar 23, 2021 · To date, anticytokine therapy has not succeeded in improving outcomes in patients with the “cytokine storm” of sepsis and/or ARDS. An ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7994048/\",\"favicon\":\"\"},{\"id\":\"51\",\"title\":\"A “Window of Therapeutic Opportunity” for Anti-Cytokine Therapy in ...\",\"description\":\"Oct 5, 2020 · The main challenge for effective administration of anti-cytokine therapy in COVID-19 will be therefore to better define a precise “window of therapeutic ...\",\"url\":\"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.572635/full\",\"favicon\":\"\"},{\"id\":\"52\",\"title\":\"Tocilizumab reduces COVID-19 mortality and pathology in a dose ...\",\"description\":\"Oct 5, 2021 · In fact, there is much debate surrounding Tcz's efficacy for the treatment of COVID-19, as many details about its use are lacking, and even an ...\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://www.nature.com/articles/s41598-021-99291-z\",\"favicon\":\"\"},{\"id\":\"53\",\"title\":\"The cytokine storm of severe influenza and development of ...\",\"description\":\"Jul 20, 2015 · Severe cytokine storm, with markedly higher levels of pro-inflammatory cytokines including interferons (IFNs), tumor necrosis factors (TNFs), ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4711683/\",\"favicon\":\"\"},{\"id\":\"54\",\"title\":\"Influenza infection, SARS, MERS and COVID-19: Cytokine storm\",\"description\":\"Dec 14, 2020 · Cytokine storm syndromes of viral origin seem to have a common pathogenesis of the imbalanced immune response with the exaggerated inflammatory reaction.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7832378/\",\"favicon\":\"\"},{\"id\":\"55\",\"title\":\"Quantification of Cytokine Storms During Virus Infections - Frontiers\",\"description\":\"For example, the H5N1 influenza virus sets off a cytokine storm, including but not limited to interferon (IFN)-β, interleukin (IL)-6, and interferon-inducible ...Abstract · Materials and Methods · Results · Discussion\",\"url\":\"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.659419/full\",\"favicon\":\"\"},{\"id\":\"56\",\"title\":\"Cytokine Storm in COVID-19: The Current Evidence and Treatment ...\",\"description\":\"Suppression of cytokine release at an early stage of disease as treatment is controversial. Application of synthetic disease-modifying antirheumatic drugs ...\u003c|separator|\u003e\",\"url\":\"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.01708/full\",\"favicon\":\"\"},{\"id\":\"57\",\"title\":\"The cytokine storm and COVID‐19 - PMC - PubMed Central\",\"description\":\"A cytokine storm is a potentially fatal immune disease characterized by the high‐level activation of immune cells and excessive production of massive ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7361342/\",\"favicon\":\"\"},{\"id\":\"58\",\"title\":\"Cytokine Storms in COVID-19, Hemophagocytic ... - JAMA Network\",\"description\":\"Apr 7, 2025 · This cohort study compares inflammatory patterns and clinical outcomes of cytokine storms in patients with COVID-19, patients receiving ...Missing:  overstated | Show results with:overstated\",\"url\":\"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2832234\",\"favicon\":\"\"},{\"id\":\"59\",\"title\":\"The pathogenesis, diagnosis, prevention, and treatment of CAR-T ...\",\"description\":\"Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are the most common adverse events during CAR-T cell therapy ...\",\"url\":\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.950923/full\",\"favicon\":\"\"},{\"id\":\"60\",\"title\":\"Cytokine release syndrome | Journal for ImmunoTherapy of Cancer\",\"description\":\"Jun 15, 2018 · This review provides a comprehensive overview of the mechanisms underlying CRS pathophysiology, risk factors, clinical presentation, differential diagnoses, ...\",\"url\":\"https://jitc.bmj.com/content/6/1/56\",\"favicon\":\"\"},{\"id\":\"61\",\"title\":\"Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal ...\",\"description\":\"Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist ...\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMoa063842\",\"favicon\":\"\"},{\"id\":\"62\",\"title\":\"Clinical Pharmacology of Cytokine Release Syndrome with T-Cell ...\",\"description\":\"Cytokine release syndrome (CRS) is a common acute toxicity in T-cell therapies, including T-cell–engaging bispecific antibodies (T-BiSp).\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11739781/\",\"favicon\":\"\"},{\"id\":\"63\",\"title\":\"Consensus recommendations on the management of toxicity ...\",\"description\":\"Specifically, BsAbs appear to be associated with a lower incidence and severity of key toxicities such as CRS and neurotoxicity than CAR T-cell therapy. As such ...Background · Summary of toxicities... · Recommendations on the... · Discussion\",\"url\":\"https://ashpublications.org/blood/article/143/16/1565/514709/Consensus-recommendations-on-the-management-of\",\"favicon\":\"\"},{\"id\":\"64\",\"title\":\"Management of Cytokine Release Syndrome (CRS) following CAR ...\",\"description\":\"Jul 1, 2025 · CRS typically occurs within the first 1–2 weeks after CAR T-cell infusion. Its pathogenesis involves a cascade of immune activation, primarily ...\",\"url\":\"https://link.springer.com/article/10.1007/s44272-025-00044-0\",\"favicon\":\"\"},{\"id\":\"65\",\"title\":\"Kinetics and biomarkers of severe cytokine release syndrome after ...\",\"description\":\"Nov 23, 2017 · CRS after CD19 CAR T-cell therapy presents with fever, hypotension, coagulopathy, and capillary leak and has been reported to occur in 54% to 91 ...\",\"url\":\"https://ashpublications.org/blood/article/130/21/2295/36661/Kinetics-and-biomarkers-of-severe-cytokine-release\",\"favicon\":\"\"},{\"id\":\"66\",\"title\":\"Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell ...\",\"description\":\"Cytokine release syndrome (CRS), resulting from rapid immune activation induced by CAR-Ts, is the most significant treatment-related toxicity. CRS initially ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S1083879118315799\",\"favicon\":\"\"},{\"id\":\"67\",\"title\":\"The primacy of the gastrointestinal tract as a target organ of acute ...\",\"description\":\"The GI tract is therefore critical to the propagation of the “cytokine storm” characteristic of acute GVHD.Primacy of the gastrointestinal... · Rationale for shielding the... · Interleukin-11\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://ashpublications.org/blood/article/95/9/2754/125533/The-primacy-of-the-gastrointestinal-tract-as-a\",\"favicon\":\"\"},{\"id\":\"68\",\"title\":\"Graft-Versus-Host Disease - StatPearls - NCBI Bookshelf - NIH\",\"description\":\"Jun 7, 2024 · Chemotherapy and radiation therapy: High-dose chemotherapy causes local tissue damage and increases circulating cytokine levels, leading to a ...Pathophysiology · Treatment Planning · Staging\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK538235/\",\"favicon\":\"\"},{\"id\":\"69\",\"title\":\"Graft Versus Host Disease (GVHD) - Medscape Reference\",\"description\":\"Dec 23, 2024 · Triple therapy with cyclosporine, short-course methotrexate (MTX), and prednisone lowers the incidence of GVHD compared with double therapy ...Practice Essentials · Pathophysiology · Etiology · Epidemiology\",\"url\":\"https://emedicine.medscape.com/article/429037-overview\",\"favicon\":\"\"},{\"id\":\"70\",\"title\":\"Cytokine mediators of chronic graft-versus-host disease - JCI\",\"description\":\"Jun 30, 2017 · This Review focuses on the cytokines that coordinate the cellular and molecular determinants of cGVHD, outlining the pivotal soluble and surface-expressed ...Abstract · Introduction · Adaptive immunity: cytokine... · Cytokine-driven effector...\",\"url\":\"https://www.jci.org/articles/view/90593\",\"favicon\":\"\"},{\"id\":\"71\",\"title\":\"The Pathophysiology and Treatment of Graft-Versus-Host Disease\",\"description\":\"Aug 19, 2021 · Ruxolitinib suppresses dysregulated inflammatory cytokine responses in chronic GVHD and is effective in patients with chronic GVHD (144); ...Acute Gvhd · Donor T Cells · Tissue Homeostasis In Gvhd\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8417310/\",\"favicon\":\"\"},{\"id\":\"72\",\"title\":\"Recent Advances in the Treatment of Graft-Versus-Host Disease\",\"description\":\"Macrophages activated in phase 1 are further activated by endotoxins translocated from damaged GI lumen leading to a cytokine storm characteristic of acute GVHD ...Gvhd Pathophysiology · Tacrolimus · T Cell Depletion\",\"url\":\"https://www.clinmedres.org/content/2/4/243\",\"favicon\":\"\"},{\"id\":\"73\",\"title\":\"The Immunology of Macrophage Activation Syndrome - Frontiers\",\"description\":\"Jan 31, 2019 · The cytokine storm results in activation of macrophages, causing hemophagocytosis, as well as contributing to multi-organ dysfunction. In ...Abstract · Introduction · Cytolytic Cell Dysfunction in MAS · Macrophages in MAS\",\"url\":\"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.00119/full\",\"favicon\":\"\"},{\"id\":\"74\",\"title\":\"Systemic Lupus Erythematosus and Cytokine Storm - SpringerLink\",\"description\":\"Aug 9, 2024 · Systemic Lupus Erythematosus and Cytokine Storm · Abstract · Introduction · SLE and MAS Pathogenesis · MAS in Childhood-Onset SLE · MAS in Adult- ...\",\"url\":\"https://link.springer.com/chapter/10.1007/978-3-031-59815-9_24\",\"favicon\":\"\"},{\"id\":\"75\",\"title\":\"Systemic Lupus Erythematosus and Cytokine Storm - PubMed\",\"description\":\"Systemic lupus erythematosus (SLE) is the prototype of autoimmune ... Systemic Lupus Erythematosus and Cytokine Storm. Adv Exp Med Biol. 2024:1448 ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/39117826/\",\"favicon\":\"\"},{\"id\":\"76\",\"title\":\"Unleashing the Cytokine Storm: A Case of Macrophage Activation ...\",\"description\":\"Jun 25, 2024 · Unleashing the Cytokine Storm: A Case of Macrophage Activation Syndrome in Systemic Lupus Erythematosus · Discussion. MAS, also referred to as ...\",\"url\":\"https://www.cureus.com/articles/258388-unleashing-the-cytokine-storm-a-case-of-macrophage-activation-syndrome-in-systemic-lupus-erythematosus\",\"favicon\":\"\"},{\"id\":\"77\",\"title\":\"Cytokine storm and targeted therapy in hemophagocytic ... - PubMed\",\"description\":\"Jul 11, 2022 · Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening systemic hyperinflammatory syndrome. The central pathogenesis is an explosive ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/35819695/\",\"favicon\":\"\"},{\"id\":\"78\",\"title\":\"Review: Cytokine Storm Syndrome: Looking Toward the Precision ...\",\"description\":\"Feb 19, 2017 · “Cytokine storm syndrome” is a diverse set of conditions unified by a clinical phenotype of systemic inflammation, multi-organ failure, ...\",\"url\":\"https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.40071\",\"favicon\":\"\"},{\"id\":\"79\",\"title\":\"Hemophagocytic lymphohistiocytosis: current treatment advances ...\",\"description\":\"Nov 7, 2024 · Hemophagocytic lymphohistiocytosis (HLH) is a rapidly progressing, life-threatening syndrome characterized by excessive immune activation, ...\",\"url\":\"https://jhoonline.biomedcentral.com/articles/10.1186/s13045-024-01621-x\",\"favicon\":\"\"},{\"id\":\"80\",\"title\":\"Autoinflammatory Diseases and Cytokine Storms-Imbalances of ...\",\"description\":\"Oct 18, 2021 · Autoinflammation and autoimmunity represent the two extremes of a continuous spectrum of pathologic conditions with numerous overlaps in different pathologies.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/34681901/\",\"favicon\":\"\"},{\"id\":\"81\",\"title\":\"Immune cartography of macrophage activation syndrome in ... - Nature\",\"description\":\"Feb 5, 2021 · A hyperinflammatory 'cytokine storm' state termed macrophage activation syndrome (MAS), culminating from a complex interplay of genetics, ...\",\"url\":\"https://www.nature.com/articles/s41584-020-00571-1\",\"favicon\":\"\"},{\"id\":\"82\",\"title\":\"A man of vision and the discovery of tumor necrosis factor - PMC\",\"description\":\"We observed the dramatic tumor hemorrhagic necrotizing effects of endotoxin on carcinogen-induced fibrosarcoma cell lines in mice. (At this time, the ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3380349/\",\"favicon\":\"\"},{\"id\":\"83\",\"title\":\"The Physiological Role of Tumor Necrosis Factor in Human ...\",\"description\":\"TNF was first discovered in 1975 by Carswell et al. Its purification in 1980,, triggered an initial surge of research interest in ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5021902/\",\"favicon\":\"\"},{\"id\":\"84\",\"title\":\"First Demonstration That Tumor Necrosis Factor (TNF) Is Central to ...\",\"description\":\"In 1985 the Rockefeller group made a surprising discovery: TNF and cachectin were one and the same. Cerami, with Bruce Beutler (1957- ) and others, went on to ...\",\"url\":\"https://centennial.rucares.org/index.php?page=Tumor_Necrosis_Factor\",\"favicon\":\"\"},{\"id\":\"85\",\"title\":\"Divergent effects of tumor necrosis factor (TNF) in sepsis\",\"description\":\"Sep 4, 2024 · Ten years after its discovery in 1975 [1], early Tumor Necrosis Factor (TNF) secretion following injection of lipopolysaccharide (LPS) or live ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11373197/\",\"favicon\":\"\"},{\"id\":\"86\",\"title\":\"Anti-cachectin/TNF monoclonal antibodies prevent septic ... - Nature\",\"description\":\"Dec 23, 1987 · Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia ... Role of the adaptive immune response in sepsis.\",\"url\":\"https://www.nature.com/articles/330662a0\",\"favicon\":\"\"},{\"id\":\"87\",\"title\":\"The biology of graft-versus-host disease: experimental systems ...\",\"description\":\"The characteristic proinflammatory cytokines released by recipient cells at this early stage of GVHD pathogenesis are tumor necrosis factor (TNF) and ...Animal Models Of Gvl: Many... · (2) Donor T-Cell Priming And... · Chronic Gvhd\u003c|separator|\u003e\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4102708/\",\"favicon\":\"\"},{\"id\":\"88\",\"title\":\"The primacy of the gastrointestinal tract as a target organ of acute ...\",\"description\":\"May 1, 2000 · Total body irradiation and acute graft versus host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood., 90 (1997) ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0006497120640897\",\"favicon\":\"\"},{\"id\":\"89\",\"title\":\"[PDF] Pathophysiologic mechanisms of acute graft-vs.-host disease\",\"description\":\"Total body irradiation effects and acute graft versus host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 90:3204, 1997 ...\u003c|separator|\u003e\",\"url\":\"https://www.astctjournal.org/article/S1083-8791%2899%2970011-X/pdf\",\"favicon\":\"\"},{\"id\":\"90\",\"title\":\"Cytokine storms in infectious diseases | Seminars in Immunopathology\",\"description\":\"Jul 3, 2017 · However, “cytokine storm” was initially coined in the early 1990s to characterize the pathological condition that accompanied organ ...\",\"url\":\"https://link.springer.com/article/10.1007/s00281-017-0640-2\",\"favicon\":\"\"},{\"id\":\"91\",\"title\":\"Sepsis: the evolution of molecular pathogenesis concepts and ...\",\"description\":\"Feb 23, 2025 · Here, we review the history of clinical trials based on evolving concepts of sepsis pathogenesis over the past half century.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11847631/\",\"favicon\":\"\"},{\"id\":\"92\",\"title\":\"Cytokine storm of graft-versus-host disease: a critical effector role for ...\",\"description\":\"Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transplant Proc. 1993 Feb;25(1 Pt 2):1216-7. Authors. J L Ferrara ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/8442093/\",\"favicon\":\"\"},{\"id\":\"93\",\"title\":\"Cytokine dysregulation as a mechanism of graft versus host disease\",\"description\":\"Most of the clinical manifestations of GVHD may in fact be due to the dysregulated production of cytokines by T cells and other inflammatory cells.Missing:  pre- | Show results with:pre-\",\"url\":\"https://www.sciencedirect.com/science/article/pii/095279159390139J\",\"favicon\":\"\"},{\"id\":\"94\",\"title\":\"Into the Eye of the Cytokine Storm - PMC - PubMed Central\",\"description\":\"Although the concept certainly predates the coining of the term, the first use of “cytokine storm” appears to be in an article published in 1993 on graft-versus ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3294426/\",\"favicon\":\"\"},{\"id\":\"95\",\"title\":\"Study shows cytokine storm in fatal 2009 H1N1 cases - CIDRAP\",\"description\":\"Aug 16, 2013 · The scientists found that the peak levels of virus in the victims' lungs correlated with \\\"remarkably\\\" high levels of certain cytokines in the ...\",\"url\":\"https://www.cidrap.umn.edu/h1n1-2009-pandemic-influenza/study-shows-cytokine-storm-fatal-2009-h1n1-cases\",\"favicon\":\"\"},{\"id\":\"96\",\"title\":\"Cytokine Response Patterns in Severe Pandemic 2009 H1N1 ... - NIH\",\"description\":\"Oct 13, 2011 · In conclusion, we found that in pH1N1 pneumonia the proinflammatory cytokines were hyperactivated, which correlated with severe symptoms and ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3192778/\",\"favicon\":\"\"},{\"id\":\"97\",\"title\":\"Delayed Clearance of Viral Load and Marked Cytokine Activation in ...\",\"description\":\"Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection.\",\"url\":\"https://academic.oup.com/cid/article/50/6/850/418325\",\"favicon\":\"\"},{\"id\":\"98\",\"title\":\"Comparing the Cytokine Storms of COVID-19 and Pandemic Influenza\",\"description\":\"This review compares cytokine storm syndromes (CSS) observed during COVID-19 and influenza to detect conserved immunopathogenic mechanisms underlying severe ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9422807/\",\"favicon\":\"\"},{\"id\":\"99\",\"title\":\"A Cause of Hyperinflammatory Response in Lethal COVID-19 ...\",\"description\":\"the extreme inflammatory response associated with increased risk of death in COVID-19 infection ...\",\"url\":\"https://www.hopkinsmedicine.org/news/newsroom/news-releases/2024/12/a-cause-of-hyperinflammatory-response-in-lethal-covid19-identified\",\"favicon\":\"\"},{\"id\":\"100\",\"title\":\"Study Details Surprising Biological Mechanisms Underlying Severe ...\",\"description\":\"Dec 2, 2024 · Severe COVID-19 arises in part from the SARS-CoV-2 virus's impact on mitochondria, tiny oxygen-burning power plants in cells, which can help trigger a cascade ...\",\"url\":\"https://news.weill.cornell.edu/news/2024/12/study-details-surprising-biological-mechanisms-underlying-severe-covid-19\",\"favicon\":\"\"},{\"id\":\"101\",\"title\":\"Frontiers and hotspots evolution in cytokine storm: A bibliometric ...\",\"description\":\"May 30, 2024 · Accumulating evidence in recent years validate the effectiveness of anti-cytokine treatment as a superior approach for managing cytokine storms.\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S240584402406986X\",\"favicon\":\"\"},{\"id\":\"102\",\"title\":\"A body–brain circuit that regulates body inflammatory responses\",\"description\":\"May 1, 2024 · ... cytokine storm and shock. The body–brain axis regulates body pro-inflammatory and anti-inflammatory immune responses following an immune insult.\",\"url\":\"https://www.nature.com/articles/s41586-024-07469-y\",\"favicon\":\"\"},{\"id\":\"103\",\"title\":\"De novo design of miniprotein antagonists of cytokine storm inducers\",\"description\":\"Aug 16, 2024 · Previous studies have shown that IL-1b can induce inflammation in hCOs that mirrors the cytokine storm caused by SARS-COV-2 infection: the ...\",\"url\":\"https://www.nature.com/articles/s41467-024-50919-4\",\"favicon\":\"\"},{\"id\":\"104\",\"title\":\"\",\"description\":\"\",\"url\":\"https://scitechdaily.com/johns-hopkins-scientists-uncover-hidden-trigger-behind-covid-19s-deadly-cytokine-storm/\",\"favicon\":\"\"},{\"id\":\"105\",\"title\":\"Repressing cytokine storm-like response in macrophages by ...\",\"description\":\"Feb 6, 2025 · Increasing eIF2α phosphorylation inhibits cytokine storm response in macrophages. This effect is mediated by transcription-translation decoupling of the ...\u003c|separator|\u003e\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S1567576924024871\",\"favicon\":\"\"},{\"id\":\"106\",\"title\":\"A citrullinated histone H3 monoclonal antibody for immune ...\",\"description\":\"Aug 12, 2025 · Treatment with hCitH3-mAb also significantly improved survival, reduced bacteria load, suppressed pro-inflammatory cytokines and protected ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12343807/\",\"favicon\":\"\"},{\"id\":\"107\",\"title\":\"\",\"description\":\"\",\"url\":\"https://doi.org/10.1038/s41467-025-62788-6\",\"favicon\":\"\"}],\"images\":[{\"id\":\"f3bf91766eb9\",\"caption\":\"Cytokine release following SARS-CoV-2 infection resulting in ARDS related to COVID-19\",\"url\":\"./_assets_/Cytokine_release_following_SARS-Cov-2_infection_resulting_in_ARDS_related_to_COVID-19.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"b18ab4892b4d\",\"caption\":\"Cytokine release following SARS-CoV-2 infection\",\"url\":\"._assets_/Cytokine_release_following_SARS-Cov-2_infection_resulting_in_ARDS_related_to_COVID-19.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"f3bf91766eb9\",\"caption\":\"Cytokine release following SARS-CoV-2 infection resulting in ARDS\",\"url\":\"./_assets_/Cytokine_release_following_SARS-Cov-2_infection_resulting_in_ARDS_related_to_COVID-19.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"f3bf91766eb9\",\"caption\":\"Cytokine release following SARS-CoV-2 infection resulting in ARDS related to COVID-19\",\"url\":\"./_assets_/Cytokine_release_following_SARS-Cov-2_infection_resulting_in_ARDS_related_to_COVID-19.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"f3bf91766eb9\",\"caption\":\"Cytokine release following SARS-CoV-2 infection resulting in ARDS related to COVID-19\",\"url\":\"./_assets_/Cytokine_release_following_SARS-Cov-2_infection_resulting_in_ARDS_related_to_COVID-19.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"f3bf91766eb9\",\"caption\":\"Cytokine release following SARS-CoV-2 infection resulting in ARDS related to COVID-19\",\"url\":\"./_assets_/Cytokine_release_following_SARS-Cov-2_infection_resulting_in_ARDS_related_to_COVID-19.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0}],\"fixedIssues\":[],\"slug\":\"Cytokine_storm\",\"title\":\"Cytokine storm\",\"content\":\"$1f\",\"description\":\"Cytokine storm\\n\\nCytokine release following SARS-CoV-2 infection resulting in ARDS related to COVID-19 \\nA cytokine storm is a life-threatening systemic inflammatory syndrome characterized by the...\",\"metadata\":{\"categories\":[\"cytokine release syndrome\",\"CRS\",\"hypercytokinemia\"],\"lastModified\":\"1761585531\",\"contentLength\":\"76146\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"96650\",\"recentViews\":\"96650\",\"dailyAvgViews\":3221.666748046875,\"qualityScore\":1,\"lastViewed\":\"1761886723\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761886723252,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Cytokine_storm\"],\"queryHash\":\"[\\\"page\\\",\\\"Cytokine_storm\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Cytokine storm\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"A cytokine storm is a life-threatening systemic inflammatory syndrome characterized by the excessive release of pro-inflammatory cytokines from overactivated immune cells, resulting in widespread endothelial dysfunction, tissue damage, and potential multi-organ failure. This dysregulated response often features elevated circulating levels of interleukins (such as IL-6 and IL-1), tumor necrosis factor-alpha (TNF-α), interferons, and chemokines, which amplify immune cell recruitment and...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"cytokine release syndrome, CRS, hypercytokinemia\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Cytokine_storm\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Cytokine storm\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"A cytokine storm is a life-threatening systemic inflammatory syndrome characterized by the excessive release of pro-inflammatory cytokines from overactivated immune cells, resulting in widespread endothelial dysfunction, tissue damage, and potential multi-organ failure. This dysregulated response often features elevated circulating levels of interleukins (such as IL-6 and IL-1), tumor necrosis factor-alpha (TNF-α), interferons, and chemokines, which amplify immune cell recruitment and...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Cytokine_storm\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Cytokine storm\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:45.531Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Cytokine storm\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"A cytokine storm is a life-threatening systemic inflammatory syndrome characterized by the excessive release of pro-inflammatory cytokines from overactivated immune cells, resulting in widespread endothelial dysfunction, tissue damage, and potential multi-organ failure. This dysregulated response often features elevated circulating levels of interleukins (such as IL-6 and IL-1), tumor necrosis factor-alpha (TNF-α), interferons, and chemokines, which amplify immune cell recruitment and...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="NmE1YjQ2MzktODk5OC00OTYzLTg3M2ItMWMzOWI5NWExZGU0">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Cytokine_storm\"}]}]\n"])</script></body></html>